US20230125894A1 - System and Method for Drug Detection in Exhaled Breath - Google Patents
System and Method for Drug Detection in Exhaled Breath Download PDFInfo
- Publication number
- US20230125894A1 US20230125894A1 US18/088,439 US202218088439A US2023125894A1 US 20230125894 A1 US20230125894 A1 US 20230125894A1 US 202218088439 A US202218088439 A US 202218088439A US 2023125894 A1 US2023125894 A1 US 2023125894A1
- Authority
- US
- United States
- Prior art keywords
- sampling unit
- housing
- exhaled breath
- subject
- collecting
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 title claims description 38
- 229940079593 drug Drugs 0.000 title claims description 20
- 239000003814 drug Substances 0.000 title claims description 20
- 238000001514 detection method Methods 0.000 title description 6
- 238000005070 sampling Methods 0.000 claims abstract description 127
- 229940088679 drug related substance Drugs 0.000 claims abstract description 61
- 239000008186 active pharmaceutical agent Substances 0.000 claims abstract description 29
- 238000004458 analytical method Methods 0.000 claims abstract description 27
- 150000001875 compounds Chemical class 0.000 claims abstract description 25
- 238000004949 mass spectrometry Methods 0.000 claims abstract description 12
- 239000012528 membrane Substances 0.000 claims description 51
- 229960001797 methadone Drugs 0.000 claims description 40
- USSIQXCVUWKGNF-UHFFFAOYSA-N 6-(dimethylamino)-4,4-diphenylheptan-3-one Chemical compound C=1C=CC=CC=1C(CC(C)N(C)C)(C(=O)CC)C1=CC=CC=C1 USSIQXCVUWKGNF-UHFFFAOYSA-N 0.000 claims description 39
- KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 claims description 27
- 229940025084 amphetamine Drugs 0.000 claims description 27
- 239000002245 particle Substances 0.000 claims description 14
- 239000002594 sorbent Substances 0.000 claims description 10
- 210000003296 saliva Anatomy 0.000 claims description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 8
- 210000004369 blood Anatomy 0.000 claims description 7
- 239000008280 blood Substances 0.000 claims description 7
- 238000004891 communication Methods 0.000 claims description 6
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 claims description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 5
- 210000004072 lung Anatomy 0.000 claims description 5
- 241000218236 Cannabis Species 0.000 claims description 4
- GVGLGOZIDCSQPN-PVHGPHFFSA-N Heroin Chemical compound O([C@H]1[C@H](C=C[C@H]23)OC(C)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4OC(C)=O GVGLGOZIDCSQPN-PVHGPHFFSA-N 0.000 claims description 4
- 229940049706 benzodiazepine Drugs 0.000 claims description 4
- 150000001557 benzodiazepines Chemical class 0.000 claims description 4
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 claims description 4
- 229960002069 diamorphine Drugs 0.000 claims description 4
- 238000002290 gas chromatography-mass spectrometry Methods 0.000 claims description 4
- 229960001736 buprenorphine Drugs 0.000 claims description 3
- RMRJXGBAOAMLHD-IHFGGWKQSA-N buprenorphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]11CC[C@]3([C@H](C1)[C@](C)(O)C(C)(C)C)OC)CN2CC1CC1 RMRJXGBAOAMLHD-IHFGGWKQSA-N 0.000 claims description 3
- 229960005181 morphine Drugs 0.000 claims description 3
- 229940127240 opiate Drugs 0.000 claims description 3
- TVYLLZQTGLZFBW-ZBFHGGJFSA-N (R,R)-tramadol Chemical compound COC1=CC=CC([C@]2(O)[C@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-ZBFHGGJFSA-N 0.000 claims description 2
- SHXWCVYOXRDMCX-UHFFFAOYSA-N 3,4-methylenedioxymethamphetamine Chemical compound CNC(C)CC1=CC=C2OCOC2=C1 SHXWCVYOXRDMCX-UHFFFAOYSA-N 0.000 claims description 2
- VAYOSLLFUXYJDT-RDTXWAMCSA-N Lysergic acid diethylamide Chemical compound C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N(CC)CC)C2)=C3C2=CNC3=C1 VAYOSLLFUXYJDT-RDTXWAMCSA-N 0.000 claims description 2
- NPPQSCRMBWNHMW-UHFFFAOYSA-N Meprobamate Chemical compound NC(=O)OCC(C)(CCC)COC(N)=O NPPQSCRMBWNHMW-UHFFFAOYSA-N 0.000 claims description 2
- -1 Tryptamines Substances 0.000 claims description 2
- 239000003263 anabolic agent Substances 0.000 claims description 2
- 229940070021 anabolic steroids Drugs 0.000 claims description 2
- KZOKOEQTKWBKOK-XHQKLZHNSA-N azidomorphine Chemical compound O([C@H]1[C@@H](CC[C@H]23)N=[N+]=[N-])C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O KZOKOEQTKWBKOK-XHQKLZHNSA-N 0.000 claims description 2
- 229930003827 cannabinoid Natural products 0.000 claims description 2
- 239000003557 cannabinoid Substances 0.000 claims description 2
- 229940065144 cannabinoids Drugs 0.000 claims description 2
- 229960003920 cocaine Drugs 0.000 claims description 2
- 229960004193 dextropropoxyphene Drugs 0.000 claims description 2
- XLMALTXPSGQGBX-GCJKJVERSA-N dextropropoxyphene Chemical compound C([C@](OC(=O)CC)([C@H](C)CN(C)C)C=1C=CC=CC=1)C1=CC=CC=C1 XLMALTXPSGQGBX-GCJKJVERSA-N 0.000 claims description 2
- 229950002454 lysergide Drugs 0.000 claims description 2
- 229960004815 meprobamate Drugs 0.000 claims description 2
- 229960004380 tramadol Drugs 0.000 claims description 2
- TVYLLZQTGLZFBW-GOEBONIOSA-N tramadol Natural products COC1=CC=CC([C@@]2(O)[C@@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-GOEBONIOSA-N 0.000 claims description 2
- 229960004242 dronabinol Drugs 0.000 claims 1
- 239000003039 volatile agent Substances 0.000 claims 1
- 239000000523 sample Substances 0.000 description 38
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 18
- 210000002700 urine Anatomy 0.000 description 15
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 14
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 14
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 12
- 229960001252 methamphetamine Drugs 0.000 description 12
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 12
- 239000010410 layer Substances 0.000 description 11
- 229920000642 polymer Polymers 0.000 description 10
- 238000012360 testing method Methods 0.000 description 10
- 239000000463 material Substances 0.000 description 9
- 210000002381 plasma Anatomy 0.000 description 9
- 150000002500 ions Chemical class 0.000 description 8
- 238000002414 normal-phase solid-phase extraction Methods 0.000 description 8
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 7
- 235000019253 formic acid Nutrition 0.000 description 7
- 239000011159 matrix material Substances 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 239000000377 silicon dioxide Substances 0.000 description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical group CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- 239000000443 aerosol Substances 0.000 description 6
- 239000007789 gas Substances 0.000 description 6
- 239000002117 illicit drug Substances 0.000 description 6
- 230000029058 respiratory gaseous exchange Effects 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 238000007792 addition Methods 0.000 description 5
- 238000000605 extraction Methods 0.000 description 5
- 239000000835 fiber Substances 0.000 description 5
- 239000003365 glass fiber Substances 0.000 description 5
- 230000014759 maintenance of location Effects 0.000 description 5
- 239000011324 bead Substances 0.000 description 4
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 4
- 229960003529 diazepam Drugs 0.000 description 4
- 238000003255 drug test Methods 0.000 description 4
- 239000000284 extract Substances 0.000 description 4
- 239000011521 glass Substances 0.000 description 4
- 230000002209 hydrophobic effect Effects 0.000 description 4
- 239000012071 phase Substances 0.000 description 4
- 238000011002 quantification Methods 0.000 description 4
- 238000002553 single reaction monitoring Methods 0.000 description 4
- 238000002470 solid-phase micro-extraction Methods 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 3
- 241000282414 Homo sapiens Species 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 238000011088 calibration curve Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- KWTSXDURSIMDCE-OABOXVCPSA-N n,n,1,1,2-pentadeuterio-3-phenylpropan-2-amine Chemical compound [2H]C([2H])C([2H])(N([2H])[2H])CC1=CC=CC=C1 KWTSXDURSIMDCE-OABOXVCPSA-N 0.000 description 3
- 239000004033 plastic Substances 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 239000013074 reference sample Substances 0.000 description 3
- 229920006395 saturated elastomer Polymers 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- 239000012855 volatile organic compound Substances 0.000 description 3
- GBBSUAFBMRNDJC-MRXNPFEDSA-N (5R)-zopiclone Chemical compound C1CN(C)CCN1C(=O)O[C@@H]1C2=NC=CN=C2C(=O)N1C1=CC=C(Cl)C=N1 GBBSUAFBMRNDJC-MRXNPFEDSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- DUGOZIWVEXMGBE-UHFFFAOYSA-N Methylphenidate Chemical compound C=1C=CC=CC=1C(C(=O)OC)C1CCCCN1 DUGOZIWVEXMGBE-UHFFFAOYSA-N 0.000 description 2
- 238000010811 Ultra-Performance Liquid Chromatography-Tandem Mass Spectrometry Methods 0.000 description 2
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 2
- 229960004538 alprazolam Drugs 0.000 description 2
- 230000003444 anaesthetic effect Effects 0.000 description 2
- 239000012491 analyte Substances 0.000 description 2
- 238000012550 audit Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000029142 excretion Effects 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 239000002324 mouth wash Substances 0.000 description 2
- 229940051866 mouthwash Drugs 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 125000006850 spacer group Chemical group 0.000 description 2
- 238000004611 spectroscopical analysis Methods 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000004704 ultra performance liquid chromatography Methods 0.000 description 2
- 239000003643 water by type Substances 0.000 description 2
- 229960000820 zopiclone Drugs 0.000 description 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
- 235000003363 Cornus mas Nutrition 0.000 description 1
- 240000006766 Cornus mas Species 0.000 description 1
- 206010012335 Dependence Diseases 0.000 description 1
- 206010013654 Drug abuse Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 238000004566 IR spectroscopy Methods 0.000 description 1
- 238000001069 Raman spectroscopy Methods 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 206010042618 Surgical procedure repeated Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 238000011953 bioanalysis Methods 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 239000000919 ceramic Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000003749 cleanliness Effects 0.000 description 1
- DGBIGWXXNGSACT-UHFFFAOYSA-N clonazepam Chemical compound C12=CC([N+](=O)[O-])=CC=C2NC(=O)CN=C1C1=CC=CC=C1Cl DGBIGWXXNGSACT-UHFFFAOYSA-N 0.000 description 1
- 229960003120 clonazepam Drugs 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000000151 deposition Methods 0.000 description 1
- 238000004807 desolvation Methods 0.000 description 1
- 239000003989 dielectric material Substances 0.000 description 1
- 229910001873 dinitrogen Inorganic materials 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000011067 equilibration Methods 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000003193 general anesthetic agent Substances 0.000 description 1
- 239000012510 hollow fiber Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 229960005015 local anesthetics Drugs 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000011418 maintenance treatment Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 230000006996 mental state Effects 0.000 description 1
- 229960001344 methylphenidate Drugs 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229920000344 molecularly imprinted polymer Polymers 0.000 description 1
- 230000003533 narcotic effect Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000013610 patient sample Substances 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 125000004079 stearyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 208000011117 substance-related disease Diseases 0.000 description 1
- 238000004416 surface enhanced Raman spectroscopy Methods 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 229920002994 synthetic fiber Polymers 0.000 description 1
- 238000005353 urine analysis Methods 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
- G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
- G01N21/65—Raman scattering
- G01N21/658—Raman scattering enhancement Raman, e.g. surface plasmons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/08—Detecting, measuring or recording devices for evaluating the respiratory organs
- A61B5/082—Evaluation by breath analysis, e.g. determination of the chemical composition of exhaled breath
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/08—Detecting, measuring or recording devices for evaluating the respiratory organs
- A61B5/097—Devices for facilitating collection of breath or for directing breath into or through measuring devices
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/41—Detecting, measuring or recording for evaluating the immune or lymphatic systems
- A61B5/412—Detecting or monitoring sepsis
-
- F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
- F01—MACHINES OR ENGINES IN GENERAL; ENGINE PLANTS IN GENERAL; STEAM ENGINES
- F01D—NON-POSITIVE DISPLACEMENT MACHINES OR ENGINES, e.g. STEAM TURBINES
- F01D1/00—Non-positive-displacement machines or engines, e.g. steam turbines
- F01D1/02—Non-positive-displacement machines or engines, e.g. steam turbines with stationary working-fluid guiding means and bladed or like rotor, e.g. multi-bladed impulse steam turbines
- F01D1/06—Non-positive-displacement machines or engines, e.g. steam turbines with stationary working-fluid guiding means and bladed or like rotor, e.g. multi-bladed impulse steam turbines traversed by the working-fluid substantially radially
- F01D1/08—Non-positive-displacement machines or engines, e.g. steam turbines with stationary working-fluid guiding means and bladed or like rotor, e.g. multi-bladed impulse steam turbines traversed by the working-fluid substantially radially having inward flow
-
- F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
- F01—MACHINES OR ENGINES IN GENERAL; ENGINE PLANTS IN GENERAL; STEAM ENGINES
- F01D—NON-POSITIVE DISPLACEMENT MACHINES OR ENGINES, e.g. STEAM TURBINES
- F01D5/00—Blades; Blade-carrying members; Heating, heat-insulating, cooling or antivibration means on the blades or the members
- F01D5/02—Blade-carrying members, e.g. rotors
- F01D5/04—Blade-carrying members, e.g. rotors for radial-flow machines or engines
- F01D5/043—Blade-carrying members, e.g. rotors for radial-flow machines or engines of the axial inlet- radial outlet, or vice versa, type
- F01D5/048—Form or construction
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01J—MEASUREMENT OF INTENSITY, VELOCITY, SPECTRAL CONTENT, POLARISATION, PHASE OR PULSE CHARACTERISTICS OF INFRARED, VISIBLE OR ULTRAVIOLET LIGHT; COLORIMETRY; RADIATION PYROMETRY
- G01J3/00—Spectrometry; Spectrophotometry; Monochromators; Measuring colours
- G01J3/28—Investigating the spectrum
- G01J3/44—Raman spectrometry; Scattering spectrometry ; Fluorescence spectrometry
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/483—Physical analysis of biological material
- G01N33/497—Physical analysis of biological material of gaseous biological material, e.g. breath
-
- F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
- F05—INDEXING SCHEMES RELATING TO ENGINES OR PUMPS IN VARIOUS SUBCLASSES OF CLASSES F01-F04
- F05D—INDEXING SCHEME FOR ASPECTS RELATING TO NON-POSITIVE-DISPLACEMENT MACHINES OR ENGINES, GAS-TURBINES OR JET-PROPULSION PLANTS
- F05D2220/00—Application
- F05D2220/60—Application making use of surplus or waste energy
- F05D2220/62—Application making use of surplus or waste energy with energy recovery turbines
-
- F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
- F05—INDEXING SCHEMES RELATING TO ENGINES OR PUMPS IN VARIOUS SUBCLASSES OF CLASSES F01-F04
- F05D—INDEXING SCHEME FOR ASPECTS RELATING TO NON-POSITIVE-DISPLACEMENT MACHINES OR ENGINES, GAS-TURBINES OR JET-PROPULSION PLANTS
- F05D2240/00—Components
- F05D2240/20—Rotors
- F05D2240/30—Characteristics of rotor blades, i.e. of any element transforming dynamic fluid energy to or from rotational energy and being attached to a rotor
- F05D2240/301—Cross-sectional characteristics
-
- F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
- F05—INDEXING SCHEMES RELATING TO ENGINES OR PUMPS IN VARIOUS SUBCLASSES OF CLASSES F01-F04
- F05D—INDEXING SCHEME FOR ASPECTS RELATING TO NON-POSITIVE-DISPLACEMENT MACHINES OR ENGINES, GAS-TURBINES OR JET-PROPULSION PLANTS
- F05D2240/00—Components
- F05D2240/40—Use of a multiplicity of similar components
-
- F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
- F05—INDEXING SCHEMES RELATING TO ENGINES OR PUMPS IN VARIOUS SUBCLASSES OF CLASSES F01-F04
- F05D—INDEXING SCHEME FOR ASPECTS RELATING TO NON-POSITIVE-DISPLACEMENT MACHINES OR ENGINES, GAS-TURBINES OR JET-PROPULSION PLANTS
- F05D2250/00—Geometry
- F05D2250/50—Inlet or outlet
- F05D2250/51—Inlet
Definitions
- This disclosure pertains in general to the field of systems and methods for collecting a sample from exhaled breath of a subject, and for detecting the presence or determining the quantitative amount of at least one drug substance in said exhaled breath. More particularly the invention relates to such portable systems.
- exhaled breath is commonly used in alcohol testing and today's technology makes it possible to perform on-site breath testing with legally defensible results using infrared spectroscopy.
- an improved apparatus, system and/or method for on-site sampling of a subject for drug substances is desired.
- Such an apparatus, system and/or method for sampling the subject for illicit drugs of abuse and/or medical drugs would be desired.
- the apparatus, system and/or method should be efficient, non-bulky, user friendly both for operators and the subject. It should further be not intruding and not invasive.
- embodiments of the present invention preferably seek to mitigate, alleviate or eliminate one or more deficiencies, disadvantages or issues in the art, such as the above-identified, singly or in any combination by providing a system and a method, according to the appended patent claims.
- a portable system configured to collect a sample from exhaled breath of a subject, and for detecting the presence or determining the quantitative amount of at least one drug substance in said exhaled breath.
- the invented system is adapted to collect the sample for further analysis using mass-spectroscopy.
- the system comprises a sampling unit and a housing arranged to hold the sampling unit.
- the sampling unit is adapted to collect non-volatile and volatile organic compounds of the at least one drug substance from the exhaled breath from the subject.
- the housing comprises at least one inlet for the subject to exhale into the housing to the sampling unit and at least one outlet for the exhaled breath to exit through.
- the exhaled breath volume is not stored in a volume for analysis of the chemical contents of the entire breath volume. Rather, traces of the drug substance are attached to a collecting element and then further analyzed from this element. Analysis is not made online of the breath volume, but of the traces in the collecting element.
- the collecting element may be removable from a housing and sent further for the analysis. Collection of the traces is made quick, a single exhalation may be sufficient. Less than 10 subsequent exhalations are more than sufficient to obtain reliable results and improve robustness of the system. This is far more convenient and quicker than any previous breath sample collection methods.
- Non-volatile and volatile compounds are transferred from the lungs, possibly carried by an aerosol.
- the non-volatile and the volatile compounds are drug substances and could be either medical drugs or legal or illegal narcotic substances.
- the drug substances are collected on-site using a portable system comprising a sampling unit.
- the collected samples could be sent to a laboratory for further analysis.
- compact on-site analysis may be performed.
- the analysis is performed using a suitable analyzing method like spectroscopy or preferably mass-spectroscopy.
- the sampling unit could either be a suitable element for collecting the non-volatile compounds or be a sampling unit comprising an element that is suitable to collect both non-volatile and volatile compounds.
- the system Since the system is small and designed to be easy to handle it can be used by any personnel on-site. Thus the system is adapted to be used instead of more intrusive tests like tests based on the much common urine or blood samples.
- the housing could be made of any material like, plastic, metal or glass as long as it is possibly to clean or make the housing aseptic.
- the housing could alternatively or in addition be made of a disposable material. In this way the housing may, after being used for sampling, and for some embodiments also as part of the analyze step, be discarded.
- Some embodiments of the invention comprise a detachable mouthpiece element connectable to the inlet and being in communication with said housing element.
- the detachable mouthpiece could be either a mouthpiece similar to the mouthpieces used by alcoholic test or a mask or any other type of mouthpieces suitable for exhaling through.
- the mouthpiece could be fitted with valves or flow sensors.
- the valve could be used to separate inspired fro expired air and also serve as a saliva trap.
- the mouthpiece could be used either for making the inhalation into the portable system easier or for sanitation when the system is not a disposable system and therefore needs to be cleaned between use.
- the housing is a Solid-phase extraction (SPE) cartridge or a SPE-column.
- the housing could also, in some embodiments be a modified type of sorbent tube to make it suitably to exhale through.
- the SPE-cartridge or SPE-column could be used as a housing comprising the sampling element or as part of or a sampling unit covered by a housing.
- the SPE-cartridge could, after being used for sampling exhaled breath, be directly placed on a manifold for extracting the drug substances from the SPE-cartridge. Hence this provides for making the workflow easier and smoother since the amount of steps during the analysis will be reduced. The risk for contaminating the sample during the handling will therefore be reduced.
- the sorbent tube could be used in a similar fashion as SPE-cartridge/column.
- the cartridge could be modified with for example larger inlets and outlets.
- the subject exhales directly into the SPE-cartridge/column or the sorbent tube and the whole cartridge or sorbent tube (being a portable system) could be sent to the laboratory to be analyzed.
- the portable system could comprise a pump arranged downstream the sampling unit.
- the pump could be placed after the housing element and before or after at least one outlet.
- the pump is arranged for helping the subject to pass the exhaled breath through the portable system.
- This breathing assistance could benefit and help test subjects that have a low or reduced breathing capacity.
- the portable system has a pressure drop through the system not higher than 2 cm water.
- the pressure drop through the system has to be as low as possible. 2 cm water is what a person diagnosed with Chronic obstructive pulmonary disease (COPD) can breath through.
- COPD Chronic obstructive pulmonary disease
- the sampling unit comprises at least one filter membrane.
- the filter membrane has preferably a mesh size to collect particles from the exhaled breath with a size of 0,2-0,7 ⁇ m. And even more preferably is the filter membrane chosen such that a pressure drop of less than 2 cm water occurs between said inlet and outlet at an exhalation flow rate of over 0 and up to 9 liters per second.
- the flow rate of a subject's exhalation depends on some parameters for example the subject's age, mental state (MR, Alzheimer's), medical condition (sepsis, Parkinson's) or other medications like benzodiazepines, opiates, neuroleptics, local anesthetics or intoxicants etc.
- the filter membrane could, after the subject has exhaled through the system, easily be removed and sent to a laboratory to be analyzed. The portable system could then be cleaned and a new filter could be put in place.
- the filter membrane could also be directly placed inside the aforementioned SPE-cartridge that is either used as a housing or as part of or a sampling unit inside a housing.
- the collected particles from the filter are analyzable by mass-spectroscopy.
- the mass-spectroscopy is the preferred method, also for other embodiments than those comprising a filter in the sampling unit, since the technology has a very high selectivity and sensibility of bioanalysis especially with regards to trace analytes in biological samples.
- the preferable interface is liquid chromatography.
- the filter membrane an electrostatic filter membrane.
- An electrostatic filter is here defined as a filter that has an electrostatic charge that has a polarity opposite the particles that should be collected from the exhaled breath.
- the filter could be made highly selective to certain drug substances.
- the filters emptied from collected particles and analyzed by dissolving the collected particles from the exhaled breath in a solvent and placing the solution on a Surface Enhanced Raman Spectroscopy (SERS)-substrate to be analyzed using Raman spectroscopy.
- SERS Surface Enhanced Raman Spectroscopy
- the analysis could also be performed using a SERS-senor such as a SERS-probe.
- the at least one filter membrane at least two filter membranes to discriminate at least two different drug substances. This is provided by having filter membranes with different filter selectivity.
- This may be provided by stacking or arranging at least two filters adjacent each other. Each filter may have different mesh types or electrostatic charges.
- the sampling unit could thus discriminate between at least two different drug substances. This could improve the analysis.
- the sampling unit comprises at least one solid-phase microextraction (SPME)-cartridge to be further analyzed using gas chromatography-mass spectroscopy GC-MS.
- SPME solid-phase microextraction
- the SPME-cartridge is a hollow fiber that is arranged such that it will trap the exhaled drug substances.
- the SPME-cartridge could then be analyzed directly using GC-MS.
- the portable system comprises a compartment for collecting saliva and/or condensate.
- the compartment could be arranged between the at least one inlet and the sampling unit and/or after the sampling unit and the at least one outlet. This may prevent clogging of the sampling unit, e.g. when having hydrophobic filters that may become saturated by condensed humidity or saliva from the exhaled breaths.
- two spaces could be formed: one space between the at least one inlet and the sampling unit and one space between the sampling unit and the at least one outlet.
- a similar compartment capable to collect condensate could be arrange communicating with the space after the sampling unit and the at least on outlet.
- compositions of the exhaled particles are believed to reflect the airway liquid fluid, which probably reflects the blood content of the drug.
- the drug substances are believed by the inventors to most likely to come from the central part of the airway system.
- the non-volatile drug substances are carried as liquid droplets (aerosol) that are formed during normal breathing by the turbulent airflow causing the airway-lining fluid to nebulize.
- the aerosols are possible to collect as exhaled breath condensates.
- the theory comes from Anesthetic studies that have showed that Anesthetic potency correlates with lipid solubility. Holds true across species and implies when a specific hydrophobic region is occupied the more soluble the anesthetic agent is in blood the faster the drug goes into the body.
- the drug substances could also be volatile as part of the exhaled breath.
- the detectable drug substance including in the noncomprehensive list comprising Amphetamines, ecstasy, Cannabis (THC and cannabinoids), Opiates heroin/morphine, 6-AM), Cocaine, Benzodiazepines, Propoxyphene, Methadone, Buprenorphine, Tramadol, LSD, Designer/Internet drugs, Kathinon, GHB, Meprobamat, Z-drugs, Tryptamines, Anabolic steroids, Alcohol/markers but are not limited to these since other illicit drugs not included in the list could should also be detectable due to similar interchanges with the human body as the above mentioned illicit drug substances.
- a method for portably collecting a sample from exhaled breath of a subject, and for detecting the presence or determining the quantitative amount of at least one drug substance in the exhaled breath.
- the method comprises collecting the sample using a system, according to the aforementioned aspect of the invention, from the subject; and analyzing the collected non-volatile and volatile compounds of the at least one drug substance using mass-spectroscopy.
- the collecting comprises collecting non-volatile and volatile compounds of the at least one drug substance from the exhaled breath from the subject in a sampling unit held in a housing of the system.
- the collecting comprising the subject exhaling into at least one inlet of the housing to the sampling unit and further to at least one outlet to exit from the housing.
- the method comprises discriminating between at least two different drug substances by means of at least two sampling elements.
- the sampling element is defined as an element for suitably collecting the drug substances. This could either be the sampling unit itself or a collecting element, such as a filter or fiber probe tip, arranged in the sampling unit.
- the method comprises collecting the at least one drug substance using at least one filter membrane arranged in the sampling unit.
- the method comprises collecting the at least one drug substance using at least one SPME-cartridge arranged in said sampling unit.
- FIG. 1 is a schematic illustration that shows an embodiment of a portable system configured to collect a sample from exhaled breath of a subject
- FIG. 2 a - c is an embodiment showing a housing with the sampling unit comprising collecting element being a filter membrane;
- FIG. 2 d is an embodiment showing a housing with a sampling unit being a collecting element being a filter membrane;
- FIG. 2 e is an embodiment showing a housing with a SPE-cartridge as part of a sampling unit
- FIG. 3 a is a schematic illustration that shows an embodiment of a portable system configured to collect a sample from exhaled breath of a subject wherein the sampling unit and the collecting element is a SPME-cartridge;
- FIG. 3 b is an embodiment showing a portable system configured to collect a sample from exhaled breath of a subject wherein the sampling unit and collecting element comprises a SPME-cartridge;
- FIG. 4 is a graph that shows the pressure drop as a function of the gas-flow using the diameter of the filter as the parameter.
- FIG. 5 is a schematic illustration illustrating an embodiment of a portable system configured to collect a sample from exhaled breath of a subject
- FIG. 6 is a flow-chart illustrating a method for using a portable system configured to collect a sample from exhaled breath of a subject
- FIG. 7 shows a chromatogram indicating the presence of amphetamine and methamphetamine in exhaled breath.
- a portable sampling system 10 is shown.
- the system comprises a housing 12 for holding the sampling unit 14 .
- the housing 12 could either be one sole element or be constructed out of two or more parts.
- the housing could be made of any material or combinations thereof such as, metal, plastic, glass or ceramics.
- the housing 12 comprises at least one inlet 15 that is designed to allow a subject to exhale in.
- the inlet is in one embodiment dimensioned to fit an optional mouth piece 11 preferably of the same size or type as a conventional mouth piece used for alcohol-test.
- the mouth piece 11 prevents contamination between subjects to sample.
- the exhaled breath will then enter a first chamber of the housing that is designed to spread or focus the exhaled breath over or onto the sampling unit 14 .
- the exhaled gas is thus conveyed in the housing 12 to the sampling unit 14 and brought into contact with the sampling unit 14 .
- the sampling unit comprises an arrangement that holds an element 13 for collecting at least one drug substance being non-volatile or volatile compounds from the volume of exhaled breath conveyed in the flow in the housing 12 .
- the collecting element 13 is a physical entity on which the drug substance is collected. Collection may in different embodiments be based on various principles, singly or in combination, comprising depositing, catching, fastening, condensing of non-volatile and/or volatile constituents on the collecting element 13 .
- the element for collecting 13 the at least one drug substance is in some embodiments a filter membrane.
- the collecting element 13 comprises an improved Solid phase micro-extraction (SPME)-cartridge.
- the collecting element 13 comprises silica, polymers, imprinted polymers, or molecule imprinted polymers.
- the selectivity of the collection element 13 can be controlled by the use of different types of collecting elements 13 .
- silica for example C4, C8 (hydrophilic) or C18 (hydrophobic) etc
- the selectivity depends on how hydrophobic the drug substances are.
- the collecting element is preferably highly crosslinked porous beads. These could be used to separate molecules depending on the size of the particle being filtered through the beads or how they bond with the surface of the polymers.
- the imprinted polymers such as molecular imprinted polymers are highly selective to a specific molecule or group of molecules with a size and shape being the same or similar to the cavities of the molecular imprinting. The cavities are made using a template and work as a selective binding sites.
- the at least one drug substance may comprise one or more drug compounds.
- the outlet 16 is, in one embodiment of the invention, the whole back of the housing 12 , which is the opening of the outlet 16 .
- the filter is in this embodiment for instance attached to the housing 12 with retaining elements, such as clips.
- the filter may also be attached to the housing 12 by means of a second housing element, which may be a ring formed element that is either screwed or slid onto the first housing element retaining the filter.
- the filter itself will then form the back outlet opening 16 of the housing 12 while it is removable kept in the housing 12 by the retainer means.
- the second housing element that is either screwed or slid onto the first housing element, comprises one central outlet 16 .
- many outlets 16 are arranged over the surface of the second outlet 16 in such a manner that the pressure drop is as low as possible when exhaling breath through the system 10 .
- the sampling unit 14 comprising the element suitably for collecting the drug substances 13 is hold in place by or made of spacer pieces attached to the walls of the housing 12 and either the sampling unit 14 or direct onto the element suitably for collecting the drug substances 13 .
- passages are created that will allow for a subject to easily exhale breath trough the portable sampling system 10 .
- the sampling unit 14 is arranged such that there is an air passage around it so that the air can still flow through the sampling unit 14 even if the comprised filter (collecting element 13 ) became saturated causing an undesired high pressure drop.
- This kind of sampling unit 14 arrangement thus further improves the exhaled breath spreading inside the housing 12 , whereby the surface of the sampling unit 12 is used more optimal.
- the system 10 comprises a pump 17 , arranged downstream the sampling unit 14 , after the housing 12 and before or after at least one outlet 16 of the housing 12 .
- the pump 17 is adapted to assists the subject to pass the exhaled breath through said system 10 .
- the pump 17 generates a negative pressure over the sampling unit 14 . For example if the subject has reduced lung capacity due to drug abuse or illness, this is advantageous.
- the sampling is assisted by the flow through the sampling unit 14 generated by the pump 17 .
- a flow sensor is arranged downstream the inlet 15 .
- the sensor could be arranged for measuring an exhaled volume or flow of exhaled breath.
- the senor may be a differential pressure sensor for measuring the differential pressure across the sampling unit 14 .
- the output from the differential pressure sensor is in non-turbulent flow linear to the flow through the sampling unit 14 with could be used to calculate the volume of exhaled breath having passed the sampling unit 14 . This could then be used for calculation of the concentration of drug substances in the exhaled breath.
- the volume data may be used for determining if sufficient volume has reached the sampling unit 14 for reliably determining the presence or the quantitative amount of a drug substance in the exhaled breath.
- Some embodiments of the system 10 comprises at least one compartment for collecting saliva and/or condensate.
- the compartment could be arranged either between said at least one inlet 15 and said sampling unit 14 and/or after said sampling unit 14 and said at least one outlet 16 .
- Negative ways could here be a wet or clogged sampling element 13 that collects the drug substances i.e. a filter membrane or a SPME-cartridge.
- FIG. 2 a is an embodiment showing a housing 12 with a outlet 16 and an mouthpiece 11 in flow communication with an inlet.
- the outlet 16 covers the main portion of the back of the housing 12 .
- the sampling unit 14 comprising a collecting element 13 , being a filter membrane, be seen through the outlet 16 .
- FIG. 2 c shows the main parts of this embodiment of the portable system 10 ; a first housing part 12 a ; a second housing part 12 b ; a sampling unit 14 comprising a filter membrane.
- the housing 12 is made of two parts the first part 12 a comprises an inlet 15 that can be in flow communication with a mouthpiece 11 and a second part 12 b with one large outlet 16 .
- FIG. 2 d is an alternative or additional embodiment showing a housing 12 comprising a sampling unit being a filter membrane.
- This embodiment comprises two parts that when attached forms a housing 12 that holds a filter membrane.
- the housing comprises an inlet 15 suitable for a mouthpiece 11 and an outlet 16 .
- This embodiment is very small, light weighted and easy to carry.
- FIG. 2 e is a further embodiment showing a housing comprising two part 12 a , 12 b with a SPE-cartridge 21 as part of a sampling unit 14 .
- the SPE-cartridge 21 comprising either silica beads, polymers or imprinted polymers for collecting the drug substance but could alternatively be fitted with a filter membrane.
- the SPE-cartridge 21 is seen sticking out through a outlet of the second part of the housing 12 b and the bottom of the SPE-cartridge 22 works as the systems outlet for the exhaled breath.
- the housing is a modified SPE-cartridge. This means that the system can be made smaller than the system showed in FIG. 2 e .
- the whole SPE-cartridge 21 can be sealed and then sent to a laboratory where it could be directly placed on a manifold which will help to reduce the handling of the samples and at the same time reduce the possibilities of the sample to be contaminated.
- FIG. 3 a is a schematic illustration that shows an embodiment of a portable system 30 configured to collect a sample from exhaled breath of a subject through an inlet 31 in flow communication with a housing 32 .
- the sampling unit is a SPME-cartridge holder 34 and the collecting element is a SPME-cartridge 33 .
- FIG. 3 b shows a further embodiment of the portable system 30 configured to collect a sample from exhaled breath of a subject by means of a SPME-cartridge 33 .
- the system comprises a housing made of two part 32 a and 32 b .
- the first housing part 32 a comprises with an inlet 31 in flow connection with a detachable mouthpiece 11 .
- the housing comprises an outlet through which the SPME-cartridge holder 34 can be observed.
- FIG. 3 b the SPME-cartridge and the housing is shown as separate items.
- sampling unit comprises a sorbent tube as the collecting element or wherein the sorbent tube is the sampling unit.
- the sorbet unit as for the SPE-cartridge case, could be the housing.
- the filter comprises a filtering membrane for the exhaled breath to diffuse through.
- the filter membrane is made of a suitable absorbing, yet gas permeable, material.
- the filter membrane will have a structure that catches and collects the drug substances being, exhaled particles, non-volatile or volatile compounds while letting gas pass through.
- the filter membrane is operable to sample or remove chemical compounds (drug substances) from the air with a high volumetric capacity while maintaining a low pressure drop across the filter substrate.
- the filter membrane could also be an electrostatic filter in some embodiments.
- the filter membrane may be of a nonwoven polymeric fibrous web that is transformed into an electret.
- the electret is a dielectric material exhibiting a quasi-permanent electric charge.
- Electret filters usually lose their charge upon long-term use. However, in the present application, the filter will not be used extensive times. A single exhalation may be sufficient to collect sufficient traces for a reliable analysis. Therefore, loss of electric charge will not be a concern in implementations of electret filter embodiments.
- the filter membrane is preferable a layered filter membrane but could also be a single layer filter membrane.
- the filter membrane may also be corrugated to enhance the filtering area within a given housing volume.
- the first layer collects droplets by absorption or particles from exhaled breath.
- it could also be from exhaled breath absorbing or condensates and the small amount of water then evaporates, thus leaving thousands of analytes from the exhaled breath on the first surface.
- the analytes may be part of an aerosol conveyed by the exhaled breath, which aerosol particles stick to the first layer. Evaporation may also take place of aerosol, which then leaves the traces of the analytes on the first layer for analysis.
- the first layer is gas permeable thus the analytes not collected on the first layer will pass through entering the second layer being a fiber like filter made of a synthetic, natural or half synthetic material.
- the second layer has a fiber density creating a surface volume. The gat will pass through the second layer that will collect the analytes by similar mechanism as described above but it could also be due to charges of the fibers that will make the analytes stick to the surface of the fibers.
- the filter could also have layers of other materials such as silica, polymers, and/or imprinted polymers but could also be other types of materials that could collect analytes from exhaled breath.
- the filter material comprises glass fibers.
- the glass fibers may be bearing a permanent electrostatic charge to improve the efficiency of the filter in the current application.
- the glass fibers may be randomly oriented.
- the glass fibers may be held in place by suitable outer layers of a different material.
- the glass fibers may also be partly melt together to provide a solid filter cartridge. A highly efficient filter for collecting traces of chemical compounds from exhaled breath may thus be provided while maintaining a low pressure drop at high exhalation rates, as desired.
- FIG. 4 is a graph 40 that shows the pressure drop in mm water Y as a function of the gas-flow X in the unit liter per minute and wherein the diameter of the filter is a parameter.
- the diameters of the filters tested are 10 mm (curve 41 ), 13 mm (curve 42 ), 16 mm (curve 43 ), 19 mm (curve 44 ) and 22 mm (curve 45 ).
- a small filter volume to extract from is preferred. This could be done, for this particular filter membrane, by making the diameter smaller. But at the same time the volume exhaled though the filter membrane should not generate a high drop of pressure.
- the filter membrane should collect drug substances from a, as large volume of one deeply exhaled breath, as possible and at the same time not generate a high pressure drop.
- a healthy person should be able to handle a pressure drop of about 20 mm of water.
- a filter size, for this particular filter membrane, of about 16 mm should be possible to use and still have an acceptable pressure drop.
- the sensitivity of the used LC/MS method and this particular filter membrane makes it possible to detect drug substances from one exhaled breath.
- the results indicates that short collecting times are possible and even shorter collecting times should be performable using this particular filter membrane since the sensitivity of the LC-MS method allows for detections of lower amounts than the measured.
- the measured amount of drug substance could also be obtained by a small filter volume to extract from. This according to what previously have been described.
- FIG. 5 is a schematic illustration illustrating an embodiment of a portable system 50 configured to collect a sample from exhaled breath of a subject 51 .
- the subject will exhale through an optional mouthpiece 52 being in flow communication with a housing 54 via at least one inlet 53 .
- the housing comprises a sampling unit 55 that could be either a collecting element or comprises a collecting element for collecting the drug substances from the exhaled breath.
- the exhaled breath exits the housing through at least one outlet 56 .
- the sampling unit 55 and/or collecting element is sent to a laboratory 57 to be analyzed.
- the housing 54 could be the sampling unit 55 .
- the sampling unit 55 could comprise more than one collecting element, and/or the housing 54 could comprise more than one sampling unit, in any combination, suitably for collecting drug substances This will make it possible to discriminate between different drug substances, thus making the analysis easier to perform.
- the sampling unit 55 comprise at least one filter membrane and at least one SPME-cartridge.
- Another combination could include a stack of filter membranes with different physical and/or chemical properties. But multiple filter could also be used by using sampling unit 55 comprising areas fitted with different filter membranes.
- sampling system and elements for collecting drug substances should be kept clean and preferable be aseptic but do not need to be sterile.
- FIG. 6 is a flow-chart illustrating a method 60 for using a portable system configured to collecting a sample 62 of exhaled breath and for detecting the presence or determining the quantitative amount 63 of at least one drug substance in the collected sample.
- the method comprises the steps of: A subject exhaling 61 into the invented portable system; a sampling unit will collect a sample 62 comprises drug substances; the collected sample will be analyzed using mass-spectroscopy 63 .
- chromatograms are shown from the identification of amphetamine (A) and methamphetamine (B) in exhaled breath from one subject after intake of “amphetamine”.
- Y are here representing response (CPS) and X time (min).
- CPS response
- min X time
- a subject will exhale 61 in and out either for a certain time or for a fixed number of times such as 1 to 10 times into a portable system.
- each exhale could be set to last for a fixed time.
- the exhalation could also be performed until a certain volume of exhaled breath has been obtained.
- a deep breath is preferred to reach exhaled breath from deep lying lung portions such as the central or the peripheral lung regions.
- the exhaled breath will then be collected 62 by the sampling unit comprising at least one element suitably for collecting drug substances before it exits the system.
- the sampling unit will then be removed so that the at least one element suitably for collecting drug substances can be analyzed 63 using an appropriate mass-spectroscopy method.
- the whole housing could be sent to be analyzed.
- the eluate was evaporated to dryness under nitrogen gas after addition of formic acid (10 ⁇ L of 10% formic acid in MeOH) and the residue was re-dissolved in 30 ⁇ L of 0.1% formic acid containing internal standard (5.94 ng amphetamined5).
- amphetamine and/or methamphetamine were detected in the expired air sample, which was in accordance with self-reported drug intake. In all cases the self-reported intake was supported by analysis of blood plasma and urine. The presence and relative levels of amphetamine and methamphetamine indicated mixed drug use of both compounds, which is in accordance with a recent trend in Sweden observed in the clinical urine drug testing. In the 8 healthy controls no amphetamine or methamphetamine were detected.
- Drug identification of detected analytes was based on a correct (relative to amphetamine-d5) retention time ( ⁇ 0.5%) and correct ( ⁇ 20%) relative ion intensity ratio between the two product ions ( FIG. 7 ). These criteria for identification are in accordance with scientific standards and are being successfully applied in urine drug testing. Since levels were generally low, background signal resulted in failure to fulfil identification criteria in some of the samples despite the fact that a signal was actually present. The amount of substance collected from expired air ranged from 0.2 to 103 pg/min for amphetamine and ⁇ 0.3 to 139 pg/min for methamphetamine, see Table 1. No correlation between plasma and expired air levels was evident from the results. However, the sampling technique employed could not be validated for extraction efficiency.
- the SPE cartridge material is normally used for extraction of analytes from aqueous solutions. It is therefore unknown to what degree the amphetamines are trapped from expired air and the reproducibility of the extraction efficiency, which may have contributed to the variability in detected amounts in the expired air samples. Firm conclusions regarding correlation of expired air with blood levels were therefore not possible in this example. Using a flow meter as described above to determine the analyzed volume would provide an efficacy measure.
- Empore disc was cut into 5 mm ⁇ 5 mm pieces using a scalpel and transferred to a 10 mL glass test-tube.
- a volume of 100 ⁇ L of 100 ng/mL methadone-d3 was added and mixed using a Vortex mixer, 300_L of 2-propanol was added (to wet the surface), mixed and finally 5 mL of 20% methanol in ethyl acetate was added. This mixture was shaken for one hour in a thermostatic bath at 37° C.
- test-tube was centrifuged for 15 min at 3000 ⁇ g at 10° C., the supernatant transferred to a new 10 mL glass test-tube, and the extraction procedure repeated using 1 mL of 20% methanol in ethyl acetate. Finally the two supernatants were combined, 10_L of 10% aqueous formic acid added and evaporated to dryness under a stream of nitrogen at a temperature of 40° C. The dry residue was dissolved in 100_L of 50% methanol in ethyl acetate.
- Mass spectrometry analysis An aliquot of 3 ⁇ L was subjected to analysis by UPLC-MS/MS (Waters Quattro Premier XE).
- the mobile phase was 95% A for 1.2 min, followed by a linear gradient from 5% B to 65% B to 3.0 min.
- the equilibration time between injections was 4.0 min (95% A).
- the flow rate was 0.20 mL/min.
- Method validation Five replications of the calibration curve were analyzed on different occasions. Limit of detection (LOD) and lower limit of quantification (LLOQ) was assessed by applying 10 pg of methadone onto a blank Empore disc and subject it for analysis. Imprecision and accuracy were estimated by analysis of six replicates of methadone applied on blank Empore discs at three levels (3.0, 15, 45 ng/disc). Recovery of extracting methadone from the Empore disc was estimated by comparison with a reference sample prepared directly in the final extract solvent. Matrix effects were estimated by extracting blank filter and filter from healthy volunteer and fortify with methadone in the final extract. This was compared with a reference sample without matrix.
- an infusion experiment was performed where injection of a control breath extract was injected while infusing methadone post-column and compared with injection of mobile phase A.
- the infusion rate was 10 ⁇ L/min and the infused methadone solution was 0.5 ⁇ g/mL in 0.1% formic acid in 50% methanol.
- the peak area ratio of methadone to methadone-d3 was linear between 3 and 60 ng per sample corresponding to 0.3 and 6.0 ng methadone exhaled in breath per min.
- LOD (signal to noise 3) was estimated to 4 pg/sample ( ⁇ 0.4 pg in breath/min) and LLOQ (signal to noise 10) was estimated to 15 pg/sample, while the calibrated measuring range was 3.0-60 ng/sample.
- Matrix effects were estimated by addition of methadone (15 ng/sample) to extracts prepared from blank Empore discs and from Empore discs used for collection of exhaled breath from a healthy volunteer.
- the methadone peak area was compared with the reference sample containing no matrix.
- Methadone was detected in the sampled exhaled breath from all 13 studied patients, which was in accordance with the daily observed dose intake of methadone (Table 2). In all cases this was also supported by compliance to treatment as controlled by routine analysis of urine and by supervised dose intake. None of the 10 control subjects had detectable levels of methadone ( ⁇ 0.005 ng/min) in the exhaled breath samples. The detection level was set by the contribution of methadone-d3 to the two methadone channels.
- Identification of detected methadone was based on a correct relative (to methadone-d3) retention time ( ⁇ 0.5%) and correct ( ⁇ 20%) relative ion intensity ratio between the two product ions.
- the amount of methadone collected from breath was high enough to produce strong analytical response. This makes the identification secure and methadone was identified according to these criteria in samples from all methadone patients.
- the amount of methadone ranged>15-fold from 0.39 to >6.0 (78) ng/min. The highest value obtained was outside the measuring range and appeared to be an outlier.
- Table 2 summarizes the results and collected data for the 13 patient samples. No difference in results could be observed between subjects sampled with or without mouth wash prior to sampling (Table 2). No significant correlation of excretion rate with methadone dose was observed.
- Table 2 Each subject was breathing at own chosen pace. The number of breaths during the 10 min sampling time was therefore recorded (Table 2). Table 2 also reports the actual sampling time after dose intake. Due to practical reasons this time interval could not be the same for all subjects but varied between 8 and 60 min.
- Empore discs are commercially available, for instance from 3M Inc. These products are made of bonded silica. They are conventionally intended for use for the solid phase extraction of liquid analytes, which usually are highly diluted. It was hitherto not known to use such collective elements as a filter discs for collecting non-volatile or volatile compounds of substances in a gas, such as exhaled breath. Present applicants have realized this unexpected potential and above example shows the feasibility of that inventive use.
- pressure drop through the commercially Empore discs is high, some embodiments are provided with the aforementioned pump assisted breathing through the discs. Alternatively, or in addition, the discs may be modified to reduce pressure drop over them. This may be done by pinching holes through a portion of the surface of the disc. Alternatively, or in addition, an Empore disc is hold in place by spacer pieces, as described above.
- a variety of functional groups such as octadecyl (C18) and octyl (C8) can be bonded to the silica surface to provide non polar interactions.
- Each of these sorbents exhibits unique properties of retention and selectivity. This is based on the fact that drug compounds are lipophilic as such because they can pass the blood-brain barrier.
- the sorbents, such as C18, render the silica surface lipophilic. Therefore, these collective elements provide for selectivity for a particular analyte, such as for a specific drug substance.
- the conjunctive phrases in the foregoing examples in which the conjunctive list consists of X, Y, and Z shall each encompass: one or more of X; one or more of Y; one or more of Z; one or more of X and one or more of Y; one or more of Y and one or more of Z; one or more of X and one or more of Z; and one or more of X, one or more of Y and one or more of Z.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Physics & Mathematics (AREA)
- General Health & Medical Sciences (AREA)
- Pathology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Medical Informatics (AREA)
- Surgery (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Heart & Thoracic Surgery (AREA)
- Animal Behavior & Ethology (AREA)
- General Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- Physiology (AREA)
- Pulmonology (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Mechanical Engineering (AREA)
- General Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Vascular Medicine (AREA)
- Sampling And Sample Adjustment (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
- Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
- Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)
Abstract
A portable system is disclosed for collecting a sample from exhaled breath of a subject. Drug substance in the exhaled breath are detected or determined. The sample is collected for further analysis using mass-spectroscopy. The system comprises a sampling unit and a housing arranged to hold the sampling unit, the sampling unit is adapted to collect non-volatile and volatile compounds of the at least one drug substance from the exhaled breath from the subject. The housing has at least one inlet for the subject to exhale into the housing to the sampling unit and at least one outlet for the exhaled breath to exit through.
Description
- This application is a continuation of U.S. patent application Ser. No. 16/678,761, filed on Nov. 8, 2019, which application was a continuation of U.S. Nonprovisional patent application Ser. No. 13/394,609, filed on May 29, 2012 (now U.S. patent Ser. No. 10/520,439), which application was a U.S. national phase of PCT Application No.: PCT/EP2010/063266 filed Sep. 9, 2010. These applications claim the benefit of priority of U.S. Provisional Patent Application Ser. No. 61/240,752, filed Sep. 9, 2009, and titled “A System and Method for Drug Detection in Exhaled Breath”. Each of these applications are incorporated by reference herein in their entirety.
- This disclosure pertains in general to the field of systems and methods for collecting a sample from exhaled breath of a subject, and for detecting the presence or determining the quantitative amount of at least one drug substance in said exhaled breath. More particularly the invention relates to such portable systems.
- It is known that exhaled breath is commonly used in alcohol testing and today's technology makes it possible to perform on-site breath testing with legally defensible results using infrared spectroscopy.
- Testing for other illicit drugs of abuse traditionally requires blood or urine samples. Alternatively specimens comprising hair, sweat or oral fluid could be used. Blood sampling is invasive and requires medically trained personnel, why test subject often have to be transported to a hospital for sampling. This is time and effort consuming. With long lead times the test result will be too old. Urine sampling is considered intruding on personal integrity. Even other issues related to samples and specimens taken from a subject to be tested arise. For instance for blood samples, and especially for urine samples are at risk of the subject exchanging the samples or using clean samples from another subject to avoid being discovered with traces of illicit drugs. Thus, there is a need to provide a non-invasive, not-specimen based apparatus, system and/or method for detecting the presence or determining the quantitative amount of at least one drug substance in a subject.
- Hence, an improved apparatus, system and/or method for on-site sampling of a subject for drug substances is desired. Such an apparatus, system and/or method for sampling the subject for illicit drugs of abuse and/or medical drugs would be desired. The apparatus, system and/or method should be efficient, non-bulky, user friendly both for operators and the subject. It should further be not intruding and not invasive.
- Accordingly, embodiments of the present invention preferably seek to mitigate, alleviate or eliminate one or more deficiencies, disadvantages or issues in the art, such as the above-identified, singly or in any combination by providing a system and a method, according to the appended patent claims.
- According to one aspect of the invention, a portable system is provided that is configured to collect a sample from exhaled breath of a subject, and for detecting the presence or determining the quantitative amount of at least one drug substance in said exhaled breath.
- The invented system is adapted to collect the sample for further analysis using mass-spectroscopy. The system comprises a sampling unit and a housing arranged to hold the sampling unit. The sampling unit is adapted to collect non-volatile and volatile organic compounds of the at least one drug substance from the exhaled breath from the subject. The housing comprises at least one inlet for the subject to exhale into the housing to the sampling unit and at least one outlet for the exhaled breath to exit through.
- The exhaled breath volume is not stored in a volume for analysis of the chemical contents of the entire breath volume. Rather, traces of the drug substance are attached to a collecting element and then further analyzed from this element. Analysis is not made online of the breath volume, but of the traces in the collecting element. The collecting element may be removable from a housing and sent further for the analysis. Collection of the traces is made quick, a single exhalation may be sufficient. Less than 10 subsequent exhalations are more than sufficient to obtain reliable results and improve robustness of the system. This is far more convenient and quicker than any previous breath sample collection methods.
- Compounds exhaled in expired air may originate from blood by a mechanism of producing a gas phase in the alveoli. Alternatively, compounds may originate from other parts of the airways. Non-volatile and volatile compounds are transferred from the lungs, possibly carried by an aerosol. Here the non-volatile and the volatile compounds are drug substances and could be either medical drugs or legal or illegal narcotic substances. The drug substances are collected on-site using a portable system comprising a sampling unit. The collected samples could be sent to a laboratory for further analysis. Alternatively, compact on-site analysis may be performed. The analysis is performed using a suitable analyzing method like spectroscopy or preferably mass-spectroscopy. The sampling unit could either be a suitable element for collecting the non-volatile compounds or be a sampling unit comprising an element that is suitable to collect both non-volatile and volatile compounds.
- Since the system is small and designed to be easy to handle it can be used by any personnel on-site. Thus the system is adapted to be used instead of more intrusive tests like tests based on the much common urine or blood samples.
- The housing could be made of any material like, plastic, metal or glass as long as it is possibly to clean or make the housing aseptic. The housing could alternatively or in addition be made of a disposable material. In this way the housing may, after being used for sampling, and for some embodiments also as part of the analyze step, be discarded.
- Some embodiments of the invention comprise a detachable mouthpiece element connectable to the inlet and being in communication with said housing element.
- The detachable mouthpiece could be either a mouthpiece similar to the mouthpieces used by alcoholic test or a mask or any other type of mouthpieces suitable for exhaling through. The mouthpiece could be fitted with valves or flow sensors. The valve could be used to separate inspired fro expired air and also serve as a saliva trap. The mouthpiece could be used either for making the inhalation into the portable system easier or for sanitation when the system is not a disposable system and therefore needs to be cleaned between use.
- In one embodiment of the portable system the housing is a Solid-phase extraction (SPE) cartridge or a SPE-column. The housing could also, in some embodiments be a modified type of sorbent tube to make it suitably to exhale through.
- The SPE-cartridge or SPE-column could be used as a housing comprising the sampling element or as part of or a sampling unit covered by a housing. The SPE-cartridge could, after being used for sampling exhaled breath, be directly placed on a manifold for extracting the drug substances from the SPE-cartridge. Hence this provides for making the workflow easier and smoother since the amount of steps during the analysis will be reduced. The risk for contaminating the sample during the handling will therefore be reduced. The sorbent tube could be used in a similar fashion as SPE-cartridge/column.
- To make it easy to exhale through the SPE-cartridge the cartridge could be modified with for example larger inlets and outlets. In one embodiment of the invention the subject exhales directly into the SPE-cartridge/column or the sorbent tube and the whole cartridge or sorbent tube (being a portable system) could be sent to the laboratory to be analyzed.
- In another embodiment of the invention, the portable system could comprise a pump arranged downstream the sampling unit.
- The pump could be placed after the housing element and before or after at least one outlet. The pump is arranged for helping the subject to pass the exhaled breath through the portable system.
- This breathing assistance could benefit and help test subjects that have a low or reduced breathing capacity.
- In yet another embodiment of the invention, the portable system has a pressure drop through the system not higher than 2 cm water. To be able to collect exhaled breath samples from most subjects the pressure drop through the system has to be as low as possible. 2 cm water is what a person diagnosed with Chronic obstructive pulmonary disease (COPD) can breath through.
- In some embodiments of the invention, the sampling unit comprises at least one filter membrane. The filter membrane has preferably a mesh size to collect particles from the exhaled breath with a size of 0,2-0,7 μm. And even more preferably is the filter membrane chosen such that a pressure drop of less than 2 cm water occurs between said inlet and outlet at an exhalation flow rate of over 0 and up to 9 liters per second.
- The flow rate of a subject's exhalation depends on some parameters for example the subject's age, mental state (MR, Alzheimer's), medical condition (sepsis, Parkinson's) or other medications like benzodiazepines, opiates, neuroleptics, local anesthetics or intoxicants etc.
- The filter membrane could, after the subject has exhaled through the system, easily be removed and sent to a laboratory to be analyzed. The portable system could then be cleaned and a new filter could be put in place. The filter membrane could also be directly placed inside the aforementioned SPE-cartridge that is either used as a housing or as part of or a sampling unit inside a housing.
- In embodiments of the invention the collected particles from the filter are analyzable by mass-spectroscopy.
- The mass-spectroscopy is the preferred method, also for other embodiments than those comprising a filter in the sampling unit, since the technology has a very high selectivity and sensibility of bioanalysis especially with regards to trace analytes in biological samples. The preferable interface is liquid chromatography.
- In another embodiment of the invention, is the filter membrane an electrostatic filter membrane.
- An electrostatic filter is here defined as a filter that has an electrostatic charge that has a polarity opposite the particles that should be collected from the exhaled breath.
- The filter could be made highly selective to certain drug substances.
- In a further embodiment of the invention is the filters emptied from collected particles and analyzed by dissolving the collected particles from the exhaled breath in a solvent and placing the solution on a Surface Enhanced Raman Spectroscopy (SERS)-substrate to be analyzed using Raman spectroscopy. The analysis could also be performed using a SERS-senor such as a SERS-probe.
- In one embodiment of the invention is the at least one filter membrane at least two filter membranes to discriminate at least two different drug substances. This is provided by having filter membranes with different filter selectivity.
- This may be provided by stacking or arranging at least two filters adjacent each other. Each filter may have different mesh types or electrostatic charges. The sampling unit could thus discriminate between at least two different drug substances. This could improve the analysis.
- In an embodiment, the sampling unit comprises at least one solid-phase microextraction (SPME)-cartridge to be further analyzed using gas chromatography-mass spectroscopy GC-MS.
- The SPME-cartridge is a hollow fiber that is arranged such that it will trap the exhaled drug substances. The SPME-cartridge could then be analyzed directly using GC-MS.
- In some embodiments of the invention the portable system comprises a compartment for collecting saliva and/or condensate. The compartment could be arranged between the at least one inlet and the sampling unit and/or after the sampling unit and the at least one outlet. This may prevent clogging of the sampling unit, e.g. when having hydrophobic filters that may become saturated by condensed humidity or saliva from the exhaled breaths.
- By arranging the sampling unit inside the housing so that the housing becomes divided, two spaces could be formed: one space between the at least one inlet and the sampling unit and one space between the sampling unit and the at least one outlet. By arranging a compartment communicating to the space between the at least one inlet and the sampling unit saliva and/or condensate formed, from the moist in the exhaled breath, on the walls of the housing and on the sampling unit can be collected. A similar compartment capable to collect condensate could be arrange communicating with the space after the sampling unit and the at least on outlet.
- This could help to avoid the sampling unit to be saturated due to becoming wet by saliva, moist and/or condensate.
- The compositions of the exhaled particles are believed to reflect the airway liquid fluid, which probably reflects the blood content of the drug. The drug substances are believed by the inventors to most likely to come from the central part of the airway system. The non-volatile drug substances are carried as liquid droplets (aerosol) that are formed during normal breathing by the turbulent airflow causing the airway-lining fluid to nebulize. The aerosols are possible to collect as exhaled breath condensates. The theory comes from Anesthetic studies that have showed that Anesthetic potency correlates with lipid solubility. Holds true across species and implies when a specific hydrophobic region is occupied the more soluble the anesthetic agent is in blood the faster the drug goes into the body. The drug substances could also be volatile as part of the exhaled breath.
- In an embodiment of the invention, is the detectable drug substance including in the noncomprehensive list comprising Amphetamines, ecstasy, Cannabis (THC and cannabinoids), Opiates heroin/morphine, 6-AM), Cocaine, Benzodiazepines, Propoxyphene, Methadone, Buprenorphine, Tramadol, LSD, Designer/Internet drugs, Kathinon, GHB, Meprobamat, Z-drugs, Tryptamines, Anabolic steroids, Alcohol/markers but are not limited to these since other illicit drugs not included in the list could should also be detectable due to similar interchanges with the human body as the above mentioned illicit drug substances.
- According to another aspect of the invention, a method is provided, for portably collecting a sample from exhaled breath of a subject, and for detecting the presence or determining the quantitative amount of at least one drug substance in the exhaled breath. The method comprises collecting the sample using a system, according to the aforementioned aspect of the invention, from the subject; and analyzing the collected non-volatile and volatile compounds of the at least one drug substance using mass-spectroscopy.
- In another embodiment of the method the collecting comprises collecting non-volatile and volatile compounds of the at least one drug substance from the exhaled breath from the subject in a sampling unit held in a housing of the system.
- In another embodiment of the method, the collecting comprising the subject exhaling into at least one inlet of the housing to the sampling unit and further to at least one outlet to exit from the housing.
- In another embodiment, the method comprises discriminating between at least two different drug substances by means of at least two sampling elements.
- The sampling element is defined as an element for suitably collecting the drug substances. This could either be the sampling unit itself or a collecting element, such as a filter or fiber probe tip, arranged in the sampling unit.
- In an embodiment, the method comprises collecting the at least one drug substance using at least one filter membrane arranged in the sampling unit.
- In an embodiment, the method comprises collecting the at least one drug substance using at least one SPME-cartridge arranged in said sampling unit.
- Further embodiments of the invention are defined in the dependent claims, wherein features for the second and subsequent aspects of the invention are as for the first aspect mutatis mutandis.
- It should be emphasized that the term “comprises/comprising” when used in this specification is taken to specify the presence of stated features, integers, steps or components but does not preclude the presence or addition of one or more other features, integers, steps, components or groups thereof.
- For the purpose of illustrating the invention, the drawings show aspects of one or more embodiments of the invention. However, it should be understood that the present invention is not limited to the precise arrangements and instrumentalities shown in the drawings, wherein:
- These and other aspects, features and advantages of which embodiments of the invention are capable of will be apparent and elucidated from the following description of embodiments of the present invention, reference being made to the accompanying drawings, in which
-
FIG. 1 is a schematic illustration that shows an embodiment of a portable system configured to collect a sample from exhaled breath of a subject; -
FIG. 2 a-c is an embodiment showing a housing with the sampling unit comprising collecting element being a filter membrane; -
FIG. 2 d is an embodiment showing a housing with a sampling unit being a collecting element being a filter membrane; -
FIG. 2 e is an embodiment showing a housing with a SPE-cartridge as part of a sampling unit; -
FIG. 3 a is a schematic illustration that shows an embodiment of a portable system configured to collect a sample from exhaled breath of a subject wherein the sampling unit and the collecting element is a SPME-cartridge; -
FIG. 3 b is an embodiment showing a portable system configured to collect a sample from exhaled breath of a subject wherein the sampling unit and collecting element comprises a SPME-cartridge; -
FIG. 4 is a graph that shows the pressure drop as a function of the gas-flow using the diameter of the filter as the parameter. -
FIG. 5 is a schematic illustration illustrating an embodiment of a portable system configured to collect a sample from exhaled breath of a subject; -
FIG. 6 is a flow-chart illustrating a method for using a portable system configured to collect a sample from exhaled breath of a subject; -
FIG. 7 shows a chromatogram indicating the presence of amphetamine and methamphetamine in exhaled breath. - Specific embodiments of the invention will now be described with reference to the accompanying drawings. This invention may, however, be embodied in many different forms and should not be construed as limited to the embodiments set forth herein; rather, these embodiments are provided so that this disclosure will be thorough and complete, and will fully convey the scope of the invention to those skilled in the art. The terminology used in the detailed description of the embodiments illustrated in the accompanying drawings is not intended to be limiting of the invention. In the drawings, like numbers refer to like elements.
- In an embodiment of the invention according to
FIG. 1 aportable sampling system 10 is shown. The system comprises ahousing 12 for holding thesampling unit 14. Thehousing 12 could either be one sole element or be constructed out of two or more parts. The housing could be made of any material or combinations thereof such as, metal, plastic, glass or ceramics. - The
housing 12 comprises at least oneinlet 15 that is designed to allow a subject to exhale in. The inlet is in one embodiment dimensioned to fit anoptional mouth piece 11 preferably of the same size or type as a conventional mouth piece used for alcohol-test. Themouth piece 11 prevents contamination between subjects to sample. - The exhaled breath will then enter a first chamber of the housing that is designed to spread or focus the exhaled breath over or onto the
sampling unit 14. The exhaled gas is thus conveyed in thehousing 12 to thesampling unit 14 and brought into contact with thesampling unit 14. - The sampling unit comprises an arrangement that holds an
element 13 for collecting at least one drug substance being non-volatile or volatile compounds from the volume of exhaled breath conveyed in the flow in thehousing 12. It should be noted that thesampling unit 14 is not to be confused with an electronic sampling unit. The collectingelement 13 is a physical entity on which the drug substance is collected. Collection may in different embodiments be based on various principles, singly or in combination, comprising depositing, catching, fastening, condensing of non-volatile and/or volatile constituents on the collectingelement 13. - The element for collecting 13 the at least one drug substance is in some embodiments a filter membrane. Alternatively, or in addition, the collecting
element 13 comprises an improved Solid phase micro-extraction (SPME)-cartridge. Alternatively, or in addition, the collectingelement 13 comprises silica, polymers, imprinted polymers, or molecule imprinted polymers. - The selectivity of the
collection element 13 can be controlled by the use of different types of collectingelements 13. When using silica (for example C4, C8 (hydrophilic) or C18 (hydrophobic) etc) either as a membrane, beads or gel, the selectivity depends on how hydrophobic the drug substances are. For polymers the collecting element is preferably highly crosslinked porous beads. These could be used to separate molecules depending on the size of the particle being filtered through the beads or how they bond with the surface of the polymers. The imprinted polymers such as molecular imprinted polymers are highly selective to a specific molecule or group of molecules with a size and shape being the same or similar to the cavities of the molecular imprinting. The cavities are made using a template and work as a selective binding sites. - The at least one drug substance may comprise one or more drug compounds.
- To allow for a low pressure drop through the
system 10 theoutlet 16 is, in one embodiment of the invention, the whole back of thehousing 12, which is the opening of theoutlet 16. The filter is in this embodiment for instance attached to thehousing 12 with retaining elements, such as clips. The filter may also be attached to thehousing 12 by means of a second housing element, which may be a ring formed element that is either screwed or slid onto the first housing element retaining the filter. The filter itself will then form the back outlet opening 16 of thehousing 12 while it is removable kept in thehousing 12 by the retainer means. - In an embodiment, the second housing element, that is either screwed or slid onto the first housing element, comprises one
central outlet 16. Alternatively, or in addition,many outlets 16 are arranged over the surface of thesecond outlet 16 in such a manner that the pressure drop is as low as possible when exhaling breath through thesystem 10. - In yet another embodiment the
sampling unit 14 comprising the element suitably for collecting thedrug substances 13 is hold in place by or made of spacer pieces attached to the walls of thehousing 12 and either thesampling unit 14 or direct onto the element suitably for collecting thedrug substances 13. Thus passages are created that will allow for a subject to easily exhale breath trough theportable sampling system 10. - In one embodiment, the
sampling unit 14 is arranged such that there is an air passage around it so that the air can still flow through thesampling unit 14 even if the comprised filter (collecting element 13) became saturated causing an undesired high pressure drop. This kind ofsampling unit 14 arrangement thus further improves the exhaled breath spreading inside thehousing 12, whereby the surface of thesampling unit 12 is used more optimal. - In some embodiments the
system 10 comprises apump 17, arranged downstream thesampling unit 14, after thehousing 12 and before or after at least oneoutlet 16 of thehousing 12. Thepump 17 is adapted to assists the subject to pass the exhaled breath through saidsystem 10. Thepump 17 generates a negative pressure over thesampling unit 14. For example if the subject has reduced lung capacity due to drug abuse or illness, this is advantageous. The sampling is assisted by the flow through thesampling unit 14 generated by thepump 17. - In some embodiments a flow sensor is arranged downstream the
inlet 15. The sensor could be arranged for measuring an exhaled volume or flow of exhaled breath. The senor may be a differential pressure sensor for measuring the differential pressure across thesampling unit 14. The output from the differential pressure sensor is in non-turbulent flow linear to the flow through thesampling unit 14 with could be used to calculate the volume of exhaled breath having passed thesampling unit 14. This could then be used for calculation of the concentration of drug substances in the exhaled breath. Alternatively, or in addition, the volume data may be used for determining if sufficient volume has reached thesampling unit 14 for reliably determining the presence or the quantitative amount of a drug substance in the exhaled breath. - Some embodiments of the
system 10 comprises at least one compartment for collecting saliva and/or condensate. The compartment could be arranged either between said at least oneinlet 15 and saidsampling unit 14 and/or after saidsampling unit 14 and said at least oneoutlet 16. This would allow for saliva comprised in the exhaled breath or condensate formed, from the moist in the exhaled breath, on thesampling unit 14 to be collected and not affect thesampling unit 14 and the comprised collectingelement 13 in any negative way. Negative ways could here be a wet orclogged sampling element 13 that collects the drug substances i.e. a filter membrane or a SPME-cartridge. -
FIG. 2 a is an embodiment showing ahousing 12 with aoutlet 16 and anmouthpiece 11 in flow communication with an inlet. Theoutlet 16 covers the main portion of the back of thehousing 12. InFIG. 2 b can thesampling unit 14 comprising a collectingelement 13, being a filter membrane, be seen through theoutlet 16.FIG. 2 c shows the main parts of this embodiment of theportable system 10; afirst housing part 12 a; asecond housing part 12 b; asampling unit 14 comprising a filter membrane. Thehousing 12 is made of two parts thefirst part 12 a comprises aninlet 15 that can be in flow communication with amouthpiece 11 and asecond part 12 b with onelarge outlet 16. -
FIG. 2 d is an alternative or additional embodiment showing ahousing 12 comprising a sampling unit being a filter membrane. This embodiment comprises two parts that when attached forms ahousing 12 that holds a filter membrane. The housing comprises aninlet 15 suitable for amouthpiece 11 and anoutlet 16. This embodiment is very small, light weighted and easy to carry. -
FIG. 2 e is a further embodiment showing a housing comprising twopart cartridge 21 as part of asampling unit 14. The SPE-cartridge 21 comprising either silica beads, polymers or imprinted polymers for collecting the drug substance but could alternatively be fitted with a filter membrane. The SPE-cartridge 21 is seen sticking out through a outlet of the second part of thehousing 12 b and the bottom of the SPE-cartridge 22 works as the systems outlet for the exhaled breath. In a further embodiment of a similar portable system the housing is a modified SPE-cartridge. This means that the system can be made smaller than the system showed inFIG. 2 e . After use, in both of the above cases, the whole SPE-cartridge 21 can be sealed and then sent to a laboratory where it could be directly placed on a manifold which will help to reduce the handling of the samples and at the same time reduce the possibilities of the sample to be contaminated. -
FIG. 3 a is a schematic illustration that shows an embodiment of aportable system 30 configured to collect a sample from exhaled breath of a subject through aninlet 31 in flow communication with ahousing 32. Wherein the sampling unit is a SPME-cartridge holder 34 and the collecting element is a SPME-cartridge 33.FIG. 3 b shows a further embodiment of theportable system 30 configured to collect a sample from exhaled breath of a subject by means of a SPME-cartridge 33. - The system comprises a housing made of two
part first housing part 32 a comprises with aninlet 31 in flow connection with adetachable mouthpiece 11. The housing comprises an outlet through which the SPME-cartridge holder 34 can be observed. InFIG. 3 b the SPME-cartridge and the housing is shown as separate items. - Another embodiment, working similar to the described SPE-cartridge embodiment, is an embodiment wherein the sampling unit comprises a sorbent tube as the collecting element or wherein the sorbent tube is the sampling unit. Alternatively the sorbet unit, as for the SPE-cartridge case, could be the housing.
- In the embodiments of the
system 10 wherein a collectingelement 13 is in form of a filter, the filter comprises a filtering membrane for the exhaled breath to diffuse through. The filter membrane is made of a suitable absorbing, yet gas permeable, material. The filter membrane will have a structure that catches and collects the drug substances being, exhaled particles, non-volatile or volatile compounds while letting gas pass through. Preferably the filter membrane is operable to sample or remove chemical compounds (drug substances) from the air with a high volumetric capacity while maintaining a low pressure drop across the filter substrate. - The filter membrane could also be an electrostatic filter in some embodiments.
- The filter membrane may be of a nonwoven polymeric fibrous web that is transformed into an electret. The electret is a dielectric material exhibiting a quasi-permanent electric charge. Electret filters usually lose their charge upon long-term use. However, in the present application, the filter will not be used extensive times. A single exhalation may be sufficient to collect sufficient traces for a reliable analysis. Therefore, loss of electric charge will not be a concern in implementations of electret filter embodiments.
- The inventors believe that there could be different mechanisms that make it possible to use the filter membrane to collect the drug substances that could be either volatile organic compounds or non-volatile organic compounds.
- The filter membrane is preferable a layered filter membrane but could also be a single layer filter membrane.
- The filter membrane may also be corrugated to enhance the filtering area within a given housing volume.
- How the collecting of the analytes work is not entirely investigated. However, applicants believe that the first layer collects droplets by absorption or particles from exhaled breath. In addition, or alternatively, it could also be from exhaled breath absorbing or condensates and the small amount of water then evaporates, thus leaving thousands of analytes from the exhaled breath on the first surface. In addition, or alternatively, the analytes may be part of an aerosol conveyed by the exhaled breath, which aerosol particles stick to the first layer. Evaporation may also take place of aerosol, which then leaves the traces of the analytes on the first layer for analysis.
- The first layer is gas permeable thus the analytes not collected on the first layer will pass through entering the second layer being a fiber like filter made of a synthetic, natural or half synthetic material. The second layer has a fiber density creating a surface volume. The gat will pass through the second layer that will collect the analytes by similar mechanism as described above but it could also be due to charges of the fibers that will make the analytes stick to the surface of the fibers.
- The filter could also have layers of other materials such as silica, polymers, and/or imprinted polymers but could also be other types of materials that could collect analytes from exhaled breath.
- In some embodiments, the filter material comprises glass fibers. The glass fibers may be bearing a permanent electrostatic charge to improve the efficiency of the filter in the current application. The glass fibers may be randomly oriented. The glass fibers may be held in place by suitable outer layers of a different material. The glass fibers may also be partly melt together to provide a solid filter cartridge. A highly efficient filter for collecting traces of chemical compounds from exhaled breath may thus be provided while maintaining a low pressure drop at high exhalation rates, as desired.
- Due to the short time of usage, there is no risk of clogging the filters or reaching an increased pressure drop due to filter clogging.
-
FIG. 4 is agraph 40 that shows the pressure drop in mm water Y as a function of the gas-flow X in the unit liter per minute and wherein the diameter of the filter is a parameter. The diameters of the filters tested are 10 mm (curve 41), 13 mm (curve 42), 16 mm (curve 43), 19 mm (curve 44) and 22 mm (curve 45). - When analyzing the filters, a small filter volume to extract from is preferred. This could be done, for this particular filter membrane, by making the diameter smaller. But at the same time the volume exhaled though the filter membrane should not generate a high drop of pressure. Preferably, the filter membrane should collect drug substances from a, as large volume of one deeply exhaled breath, as possible and at the same time not generate a high pressure drop. A healthy person should be able to handle a pressure drop of about 20 mm of water. According to
FIG. 4 a filter size, for this particular filter membrane, of about 16 mm should be possible to use and still have an acceptable pressure drop. By modifying the physical or the chemical properties of the filter membrane or remove layers, smaller diameters may be possible. - The sensitivity of the used LC/MS method and this particular filter membrane makes it possible to detect drug substances from one exhaled breath.
- Below is a table (table 3) showing results from a pre-study on five subjects at three different occasions. Here methadone (Mtd) in exhaled breath in pictogram per minute of exhalation is measured from the five subjects using three different collecting times, one collecting time at each occasion. All measurements were performed after the subject had their individual dose of methadone delivered to them.
-
TABLE 3 Case Methadone Mtd pg/min Mtd pg/min Mtd pg/min no dose (mg/d) 1 min 3 min 10 min 1 90 200 170 3840 2 120 50 40 27 3 100 10900 233 150 4 110 100 167 120 5 100 220 117 90 - At the first occasion the subject exhaled for one minute, at the second occasion for three minutes and at the third occasion for 10 minutes. Except for subject number two who was not compliant and the exceptionally high values for subject number three and one at one of the occasions respectively, the results indicates that short collecting times are possible and even shorter collecting times should be performable using this particular filter membrane since the sensitivity of the LC-MS method allows for detections of lower amounts than the measured. The measured amount of drug substance could also be obtained by a small filter volume to extract from. This according to what previously have been described.
-
FIG. 5 is a schematic illustration illustrating an embodiment of aportable system 50 configured to collect a sample from exhaled breath of a subject 51. The subject will exhale through anoptional mouthpiece 52 being in flow communication with ahousing 54 via at least oneinlet 53. The housing comprises asampling unit 55 that could be either a collecting element or comprises a collecting element for collecting the drug substances from the exhaled breath. The exhaled breath exits the housing through at least oneoutlet 56. Thesampling unit 55 and/or collecting element is sent to alaboratory 57 to be analyzed. In some embodiments of theportable system 50 thehousing 54 could be thesampling unit 55. - The
sampling unit 55 could comprise more than one collecting element, and/or thehousing 54 could comprise more than one sampling unit, in any combination, suitably for collecting drug substances This will make it possible to discriminate between different drug substances, thus making the analysis easier to perform. For example could thesampling unit 55 comprise at least one filter membrane and at least one SPME-cartridge. Another combination could include a stack of filter membranes with different physical and/or chemical properties. But multiple filter could also be used by usingsampling unit 55 comprising areas fitted with different filter membranes. - The sampling system and elements for collecting drug substances should be kept clean and preferable be aseptic but do not need to be sterile.
-
FIG. 6 is a flow-chart illustrating amethod 60 for using a portable system configured to collecting asample 62 of exhaled breath and for detecting the presence or determining thequantitative amount 63 of at least one drug substance in the collected sample. The method comprises the steps of: A subject exhaling 61 into the invented portable system; a sampling unit will collect asample 62 comprises drug substances; the collected sample will be analyzed using mass-spectroscopy 63. - In
FIG. 7 , chromatograms are shown from the identification of amphetamine (A) and methamphetamine (B) in exhaled breath from one subject after intake of “amphetamine”. Y are here representing response (CPS) and X time (min). The conventionally analyzed urine and plasma data of the same subject taken for comparison reasons suggest possible intake of methamphetamine with amphetamine. Identification using a sampling unit and LC-MS-MS analysis was based on the presence of compounds with correct retention time and with correct relative abundance of two product ions. The identification of detected analytes was based on a correct relative (to amphetamine-d5) retention time. Two product ions from the protonated molecules were monitored for amphetamine (m/z 136->119, Plot No. 75; 136->91 73) two for methamphetamine (m/z 150->119, Plot No. 76; 150->91, Plot No. 74). None of the control subjects without drug intake showed any of these peaks when analyzed from the implemented sampling unit. Thus, detection of amphetamine (A) and methamphetamine (B) in exhaled breath samples is reliably demonstrated. Further examples are given below. - With reference to
FIG. 6 a flow-scheme is used to illustrate the invented method. A subject will exhale 61 in and out either for a certain time or for a fixed number of times such as 1 to 10 times into a portable system. When breathing a fixed number of times each exhale could be set to last for a fixed time. The exhalation could also be performed until a certain volume of exhaled breath has been obtained. A deep breath is preferred to reach exhaled breath from deep lying lung portions such as the central or the peripheral lung regions. - The exhaled breath will then be collected 62 by the sampling unit comprising at least one element suitably for collecting drug substances before it exits the system. The sampling unit will then be removed so that the at least one element suitably for collecting drug substances can be analyzed 63 using an appropriate mass-spectroscopy method. Alternatively, for some of the previously described embodiments, the whole housing could be sent to be analyzed.
- In the following further examples of implementations of the invention and how an analysis may be performed is demonstrated. These original observations demonstrate drug testing based on sampling of expired air.
- Twelve patients reporting recent use of amphetamine (7 male, 5 female, ages 22-51) were recruited from two addiction treatment clinics in Stockholm (Beroendecentrum Stockholm). History of drug use was assessed by interview and by using two structured questionnaires, AUDIT (for alcohol) and DUDIT (for illicit drugs). The patients scored a median of 2.5 (range 0-34) in the AUDIT and 34.5 (range 12-43) in the DUDIT questionnaires. Recent drug intake was further investigated by analysis of blood plasma and urine samples. The urine and EDTA plasma samples were collected following the expired air sampling and stored at −80° C.
- As control group eight drug-free healthy volunteers (3 male, 5 female, ages 29-67) were recruited. Compounds in expired air were collected by suction through an SPE cartridge (30 mg SPEC DAS, Varian, Lake Forest, Calif.). The patients were asked to breath in a face mask (no 1516, Intersurgical Ltd, Berkshire, U K) and a three way coupling was used to withdraw breath air. It was estimated that about half of the expired air was collected into the SPE cartridge via a 3 m long plastic tubing. Following sampling the SPE cartridge was stored at −80° C. and subsequently eluted with 2% ammonia (25%) in a mixture of methanol and ethyl acetate (20/80) at the time of analysis. The eluate was evaporated to dryness under nitrogen gas after addition of formic acid (10 μL of 10% formic acid in MeOH) and the residue was re-dissolved in 30 μL of 0.1% formic acid containing internal standard (5.94 ng amphetamined5).
- An aliquot of 3 μL was subjected to analysis by SRM UPLC-MS/MS (Waters Quattro Premiere XE). The chromatographic system was a AQUITY UPLC BEH C18 column, 100 mm×1.0 mm,
particle size 1,7 μm, with a gradient system with A=0.1% formic acid and B=acetonitrile. The linear gradient started at 100% A and ended at 70% A after 1.7 min. Thereafter 100% was pumped for 0.49 min before returning to 100% A. - Two product ions from the protonated molecules were monitored for amphetamine (m/z 136→119 75; 136→91 73), two for methamphetamine (m/z 150→119 76; 150→91 74) and one for amphetamine-d5 (m/z 141→124 71, 72) was done by selected reaction monitoring (SRM) in the positive electrospray mode, with 25 ms dwell time for each channel. The source block and desolvation temperatures were set at 150 and 350° C. respectively. Standards for quantification were prepared by using the matrix from blank SPE cartridges. Methods used for plasma and urine analysis were in routine use in the laboratory and based on LC-MS techniques.
- In all 12 studied patients amphetamine and/or methamphetamine were detected in the expired air sample, which was in accordance with self-reported drug intake. In all cases the self-reported intake was supported by analysis of blood plasma and urine. The presence and relative levels of amphetamine and methamphetamine indicated mixed drug use of both compounds, which is in accordance with a recent trend in Sweden observed in the clinical urine drug testing. In the 8 healthy controls no amphetamine or methamphetamine were detected.
- Drug identification of detected analytes was based on a correct (relative to amphetamine-d5) retention time (±0.5%) and correct (<±20%) relative ion intensity ratio between the two product ions (
FIG. 7 ). These criteria for identification are in accordance with scientific standards and are being successfully applied in urine drug testing. Since levels were generally low, background signal resulted in failure to fulfil identification criteria in some of the samples despite the fact that a signal was actually present. The amount of substance collected from expired air ranged from 0.2 to 103 pg/min for amphetamine and <0.3 to 139 pg/min for methamphetamine, see Table 1. No correlation between plasma and expired air levels was evident from the results. However, the sampling technique employed could not be validated for extraction efficiency. The SPE cartridge material is normally used for extraction of analytes from aqueous solutions. It is therefore unknown to what degree the amphetamines are trapped from expired air and the reproducibility of the extraction efficiency, which may have contributed to the variability in detected amounts in the expired air samples. Firm conclusions regarding correlation of expired air with blood levels were therefore not possible in this example. Using a flow meter as described above to determine the analyzed volume would provide an efficacy measure. - The urine and plasma data indicated that in most cases sampling was performed close to intake (<24h), while in other cases low levels (<˜5 μg/mL) in urine indicated longer times since intake (Table 1). Analytes were, however, still detected in the expired air. The relative proportion of amphetamine and methamphetamine in the expired air correlated well with plasma results, which further validates these findings.
- Thirteen patients undergoing methadone maintenance treatment (12 males, 1 female, ages 31-58) were recruited from the methadone program in Stockholm (Rosenlund, Stockholm). The patients were in steady-state and received supervised daily doses of methadone between 70 and 155 mg. The patients were subjected to constant control of compliance to treatment by urine drug testing. As a control group ten drug-free healthy volunteers (4 males, 6 females, ages 29-66) were recruited.
-
TABLE 1 Expired Case Self-reported Plasma* Urine* air* no drug use ng/mL μg/mL pg/min 1 Amphetamine, diazepam A = 166 A = 107 A = 0.7 M = 1.9 M = 0.69 M < 0.3 2 Amphetamine, diazepam A = 62.4 A = 14 A = 0.2 M = 0.6 M = 0.08 M < 0.3 3 Amphetamine A = 282 A = 30 A = 0.5 M = 2.1 M = 0.12 M < 0.3 4 Amphetamine, methyl- A = 110 A = 62 A = 19 phenidate M = 27 M = 5.4 M = 1.2 5 Amphetamine, zopiclone A = 52 A = 29 A = 0.4 M = 52 M = 19 M = 0.4 6 Amphetamine, fumitrazepam, No sample A = 5.3 A= 103 alprazolam, buprenorphine, M = 62 M = 139 morphine, zopiclone 7 Amphetamine A = 4.3 A = 0.94 A < 0.6 M = 3.2 M = 0.40 M = 0.5 8 Amphetamine, diazepam, No sample A = 20 A < 0.3 methadone, heroin M = 119 M = 0.6 9 Amphetamine, methylphenidate, No sample A = 6.7 A = 0.4 alprazolam, diazepam M = 0.02 M < 0.3 10 Amphetamine, fumitrazepam, A = 535 A = 229 A = 0.7 methadone M = 64 M = 15 M < 0.3 11 Amphetamine, clonazepam, A = 504 A = 163 A = 5.3 methadone, cannabis M = 274 M = 51 M = 1.3 12 Amphetamine, benzodiazepines, A = 2.0 A = 1.3 A = 1.4 heroin, cannabis M = 0.1 M = 0.01 M = 0.3 *A = amphetamine, M = methamphetamine - Sampling of Exhaled Breath
- Compounds present in the exhaled breath were collected for 10 min by suction through a 47 mm Empore C18 disc (from 3M Inc.) using a membrane pump to assist the flow (about 300 mL/min). The subjects were asked to breathe more deeply than normal into a mouth piece (no. 4091148, Palmenco AB, Stockholm, Sweden) mounted in the sampling device holding the Empore disc (
FIG. 1 ). It was estimated that all the exhaled breath was collected through the filter during the sampling period. Following sampling the Empore disc was dismantled using a tweezers and stored at −80° C. The sampling device was carefully cleaned between uses, which takes about 15 min. - Sample preparation: Following storage the Empore disc was cut into 5 mm×5 mm pieces using a scalpel and transferred to a 10 mL glass test-tube. A volume of 100 μL of 100 ng/mL methadone-d3 was added and mixed using a Vortex mixer, 300_L of 2-propanol was added (to wet the surface), mixed and finally 5 mL of 20% methanol in ethyl acetate was added. This mixture was shaken for one hour in a thermostatic bath at 37° C. Thereafter, the test-tube was centrifuged for 15 min at 3000×g at 10° C., the supernatant transferred to a new 10 mL glass test-tube, and the extraction procedure repeated using 1 mL of 20% methanol in ethyl acetate. Finally the two supernatants were combined, 10_L of 10% aqueous formic acid added and evaporated to dryness under a stream of nitrogen at a temperature of 40° C. The dry residue was dissolved in 100_L of 50% methanol in ethyl acetate.
- Mass spectrometry analysis: An aliquot of 3 μL was subjected to analysis by UPLC-MS/MS (Waters Quattro Premier XE). The chromatographic system was a Aquity UPLC BEH C18 column, 100 mm×1.0 mm, particle size 1.7 μm, with a gradient system consisting of A=0.1% formic acid and B=acetonitrile. The mobile phase was 95% A for 1.2 min, followed by a linear gradient from 5% B to 65% B to 3.0 min. The equilibration time between injections was 4.0 min (95% A). The flow rate was 0.20 mL/min. Two product ions from the protonated molecules were monitored for methadone (m/z 310→265; 310→105) and one for methadone-d3 (m/z 313→268). This was done by SRM in the positive electrospray mode, with 75 ms dwell time for each channel. The minimum detectable amount (signal to noise 3) injected on column was about ˜0.2 pg.
- Quantification: Standards for quantification were prepared from fortified blank Empore discs. These were prepared by adding 10, 25, 50, 100 and 200 μL (corresponds to 3.0, 7.5, 15, 30 and 60 ng on the surface) of a solution containing 300 ng/mL of methadone. After drying the discs were prepared for analysis as described above. Calibration curves were constructed using linear regression analysis, with
weighting factor 1/x. - Method validation: Five replications of the calibration curve were analyzed on different occasions. Limit of detection (LOD) and lower limit of quantification (LLOQ) was assessed by applying 10 pg of methadone onto a blank Empore disc and subject it for analysis. Imprecision and accuracy were estimated by analysis of six replicates of methadone applied on blank Empore discs at three levels (3.0, 15, 45 ng/disc). Recovery of extracting methadone from the Empore disc was estimated by comparison with a reference sample prepared directly in the final extract solvent. Matrix effects were estimated by extracting blank filter and filter from healthy volunteer and fortify with methadone in the final extract. This was compared with a reference sample without matrix. In addition, an infusion experiment was performed where injection of a control breath extract was injected while infusing methadone post-column and compared with injection of mobile phase A. The infusion rate was 10 μL/min and the infused methadone solution was 0.5 μg/mL in 0.1% formic acid in 50% methanol.
- The peak area ratio of methadone to methadone-d3 was linear between 3 and 60 ng per sample corresponding to 0.3 and 6.0 ng methadone exhaled in breath per min. The correlation coefficients (r2) of the calibration curves were between 0.991 and 0.999 (mean 0.996, n=5).
-
TABLE 2 Summary of data obtained for methadone sampled in exhaled breath from 13 methadone maintenance patients. Sampling Number Methadone time after Mouth wash Methadone Case of dose dose intake prior to excretion no. breaths (mg/d) (min) sampling (ng/min) 1 90 41 13 No 1.0 2 100 59 44 Yes 0.39 3 100 127 27 No 1.9 4 140 91 10 Yes 5.8 5 80 94 25 Yes 1.2 6 155 45 10 Yes 0.87 7 100 42 60 Yes 3.5 8 100 56 13 Yes 1.5 9 120 35 >10a No 1.4 10 70 46 12 Yes 0.90 11 100 66 13 Yes 0.93 12 100 90 18 Yes >6.0b 13 120 59 8 Yes 2.6 aNot noted bExtrapoled value from 180 ng/disc standard was 78 - Summary of data obtained for methadone sampled in exhaled breath from 13 methadone maintenance patients.
- LOD (signal to noise 3) was estimated to 4 pg/sample (˜0.4 pg in breath/min) and LLOQ (signal to noise 10) was estimated to 15 pg/sample, while the calibrated measuring range was 3.0-60 ng/sample. Imprecision (coefficient of variation, CV) was estimated within series to 1.6%, 1.9% and 2.0% at levels 3.0, 15, and 45 ng/sample (n=6). The accuracy was 104%, 109% and 104%, respectively. The extraction recovery of methadone from the Empore disc surface was measured in duplicate using samples at the 15 ng/sample level and was 96.6% (n=4). Matrix effects were estimated by addition of methadone (15 ng/sample) to extracts prepared from blank Empore discs and from Empore discs used for collection of exhaled breath from a healthy volunteer. The methadone peak area was compared with the reference sample containing no matrix. The matrix effect for blank Empore discs was 109% (SD 9, n=8) and for breath sample discs 108% (
SD 40, n=8). - Application of the method: Methadone was detected in the sampled exhaled breath from all 13 studied patients, which was in accordance with the daily observed dose intake of methadone (Table 2). In all cases this was also supported by compliance to treatment as controlled by routine analysis of urine and by supervised dose intake. None of the 10 control subjects had detectable levels of methadone (<0.005 ng/min) in the exhaled breath samples. The detection level was set by the contribution of methadone-d3 to the two methadone channels.
- Identification of detected methadone was based on a correct relative (to methadone-d3) retention time (±0.5%) and correct (<±20%) relative ion intensity ratio between the two product ions. The amount of methadone collected from breath was high enough to produce strong analytical response. This makes the identification secure and methadone was identified according to these criteria in samples from all methadone patients. The amount of methadone ranged>15-fold from 0.39 to >6.0 (78) ng/min. The highest value obtained was outside the measuring range and appeared to be an outlier. Table 2 summarizes the results and collected data for the 13 patient samples. No difference in results could be observed between subjects sampled with or without mouth wash prior to sampling (Table 2). No significant correlation of excretion rate with methadone dose was observed.
- Each subject was breathing at own chosen pace. The number of breaths during the 10 min sampling time was therefore recorded (Table 2). Table 2 also reports the actual sampling time after dose intake. Due to practical reasons this time interval could not be the same for all subjects but varied between 8 and 60 min.
- The Empore discs are commercially available, for instance from 3M Inc. These products are made of bonded silica. They are conventionally intended for use for the solid phase extraction of liquid analytes, which usually are highly diluted. It was hitherto not known to use such collective elements as a filter discs for collecting non-volatile or volatile compounds of substances in a gas, such as exhaled breath. Present applicants have realized this unexpected potential and above example shows the feasibility of that inventive use. As pressure drop through the commercially Empore discs is high, some embodiments are provided with the aforementioned pump assisted breathing through the discs. Alternatively, or in addition, the discs may be modified to reduce pressure drop over them. This may be done by pinching holes through a portion of the surface of the disc. Alternatively, or in addition, an Empore disc is hold in place by spacer pieces, as described above.
- A variety of functional groups, such as octadecyl (C18) and octyl (C8) can be bonded to the silica surface to provide non polar interactions.
- Each of these sorbents exhibits unique properties of retention and selectivity. This is based on the fact that drug compounds are lipophilic as such because they can pass the blood-brain barrier. The sorbents, such as C18, render the silica surface lipophilic. Therefore, these collective elements provide for selectivity for a particular analyte, such as for a specific drug substance.
- The choice of which sorbent is best for a particular method will be influenced by the percent recovery of analyte from the sample matrix and the cleanliness of the resulting chromatography.
- The present invention has been described above with reference to specific embodiments. However, other embodiments than the above described are equally possible within the scope of the invention. Different method steps than those described above, performing the method by hardware or software, may be provided within the scope of the invention. The different features and steps of the invention may be combined in other combinations than those described. The scope of the invention is only limited by the appended patent claims.
- The foregoing has been a detailed description of illustrative embodiments of the invention. It is noted that in the present specification and claims appended hereto, conjunctive language such as is used in the phrases “at least one of X, Y and Z” and “one or more of X, Y, and Z,” unless specifically stated or indicated otherwise, shall be taken to mean that each item in the conjunctive list can be present in any number exclusive of every other item in the list or in any number in combination with any or all other item(s) in the conjunctive list, each of which may also be present in any number. Applying this general rule, the conjunctive phrases in the foregoing examples in which the conjunctive list consists of X, Y, and Z shall each encompass: one or more of X; one or more of Y; one or more of Z; one or more of X and one or more of Y; one or more of Y and one or more of Z; one or more of X and one or more of Z; and one or more of X, one or more of Y and one or more of Z.
- Various modifications and additions can be made without departing from the spirit and scope of this invention. Features of each of the various embodiments described above may be combined with features of other described embodiments as appropriate in order to provide a multiplicity of feature combinations in associated new embodiments. Furthermore, while the foregoing describes a number of separate embodiments, what has been described herein is merely illustrative of the application of the principles of the present invention. Additionally, although particular methods herein may be illustrated and/or described as being performed in a specific order, the ordering is highly variable within ordinary skill to achieve aspects of the present disclosure. Accordingly, this description is meant to be taken only by way of example, and not to otherwise limit the scope of this invention.
- Exemplary embodiments have been disclosed above and illustrated in the accompanying drawings. It will be understood by those skilled in the art that various changes, omissions and additions may be made to that which is specifically disclosed herein without departing from the spirit and scope of the present invention.
Claims (20)
1. A portable system configured to collect a sample from exhaled breath of a subject, and for detecting the presence or determining the quantitative amount of at least one drug substance in said exhaled breath,
said system being adapted to collect said sample for further analysis using mass-spectroscopy, said system comprising:
a sampling unit and a housing arranged to hold said sampling unit,
said sampling unit is adapted to collect at least one of non-volatile and volatile compounds of said at least one drug substance from said exhaled breath from said subject; and
wherein said housing comprises at least one inlet for said subject to exhale into said housing to said sampling unit and at least one outlet for said exhaled breath to exit through.
2. The system according to claim 1 , comprising a detachable mouthpiece element connectable to said inlet in communication with said housing element.
3. The system according to claim 1 , wherein said housing is a SPE cartridge.
4. The system according to claim 1 , wherein said housing is a sorbent tube.
5. The system according to claim 1 , comprising a pump, wherein said pump is arranged downstream said sampling unit.
6. The system according to claim 1 , wherein the pressure drop through said system is not higher than 2 cm water.
7. The system according to claim 1 , wherein said sampling unit comprises at least one filter membrane.
8. The system according to claim 7 , wherein said filter membrane is has a mesh size to collect particles from said exhaled breath with a size of 0.2-0.7 μm.
9. The system according to claim 7 , wherein said filter membrane is configured such that a pressure drop of less than 2 cm water occurs between said inlet and outlet at a exhalation flow rate of about 0-9 litre/min.
10. The system according to claim 7 , wherein said collected particles from said filter are analyzable by said mass-spectroscopy.
11. The system according to claim 7 , wherein said filter membrane is a electrostatic filter membrane.
12. The system according to claim 7 , wherein said at least on filter membrane comprises at least two filter membranes configured to discriminate between at least two different drug substances.
13. The system according to claim 1 , wherein said sampling unit comprises at least one SPME-cartridge to be further analyzed using GC-MS.
14. The system according to claim 1 , wherein a compartment for collecting at least one of saliva or condensate is disposed between said at least one inlet and said sampling unit and/or after said sampling unit and said at least one outlet.
15. The system according to claim 1 , wherein said at least one of non-volatile or volatile compounds of said at least one drug substance in said exhaled breath are compounds that can pass from the subject's blood via the lung membrane.
16. The system according to claim 15 , wherein said drug substance comprises at least one of Amphetamine, ecstasy, Cannabis, THC and cannabinoids, Opiates, heroin, morphine, 6-AM, Cocaine, Benzodiazepines, Propoxyphene, Methadone, Buprenorphine, Tramadol, LSD, Designer/Internet drugs, Kathinon, GHB, Meprobamat, Z-drugs, Tryptamines, Anabolic steroids, Alcohol, or markers for alcohol.
17. A method for portably collecting a sample from exhaled breath of a subject, and for detecting the presence or determining the quantitative amount of at least one drug substance in said exhaled breath, said method comprising:
collecting said sample comprising at least one of a non-volatile or volatile compound from said subject, using a system comprising a sampling unit and a housing arranged to hold said sampling unit, wherein said sampling unit is adapted to collect at least one of non-volatile and volatile compounds of said at least one drug substance from said exhaled breath from said subject, and in said housing comprises at least one inlet for said subject to exhale into said housing to said sampling unit and at least one outlet for said exhaled breath to exit through; and
analyzing said collected sample using mass-spectroscopy.
18. The method according to claim 17 , wherein said collecting comprises collecting at least one of non-volatile or volatile compounds of said at least one drug substance from said exhaled breath from said subject in a sampling unit held in a housing of said system.
19. The method according to claim 18 , wherein said collecting comprises said subject exhaling into at least one inlet of said housing to said sampling unit and further to at least one outlet to exit from said housing.
20. The method according to claim 17 , comprising generating suction by means of a pump arranged downstream said sampling unit.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US18/088,439 US20230125894A1 (en) | 2009-09-09 | 2022-12-23 | System and Method for Drug Detection in Exhaled Breath |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US24075209P | 2009-09-09 | 2009-09-09 | |
PCT/EP2010/063266 WO2011029889A1 (en) | 2009-09-09 | 2010-09-09 | Drug detection in exhaled breath |
US201213394609A | 2012-05-29 | 2012-05-29 | |
US16/678,761 US11567011B2 (en) | 2009-09-09 | 2019-11-08 | System and method for drug detection in exhaled breath |
US18/088,439 US20230125894A1 (en) | 2009-09-09 | 2022-12-23 | System and Method for Drug Detection in Exhaled Breath |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/678,761 Continuation US11567011B2 (en) | 2009-09-09 | 2019-11-08 | System and method for drug detection in exhaled breath |
Publications (1)
Publication Number | Publication Date |
---|---|
US20230125894A1 true US20230125894A1 (en) | 2023-04-27 |
Family
ID=43037755
Family Applications (6)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/394,979 Expired - Fee Related US8368883B2 (en) | 2009-09-09 | 2010-09-09 | System and method for detection of analytes in exhaled breath |
US13/394,609 Expired - Fee Related US10520439B2 (en) | 2009-09-09 | 2010-09-09 | System and method for drug detection in exhaled breath |
US13/739,607 Active US8705029B2 (en) | 2009-09-09 | 2013-01-11 | System and method for detection of analytes in exhaled breath |
US14/222,696 Abandoned US20140204374A1 (en) | 2009-09-09 | 2014-03-24 | System and Method for Detection of Analytes in Exhaled Breath |
US16/678,761 Active 2031-10-03 US11567011B2 (en) | 2009-09-09 | 2019-11-08 | System and method for drug detection in exhaled breath |
US18/088,439 Pending US20230125894A1 (en) | 2009-09-09 | 2022-12-23 | System and Method for Drug Detection in Exhaled Breath |
Family Applications Before (5)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/394,979 Expired - Fee Related US8368883B2 (en) | 2009-09-09 | 2010-09-09 | System and method for detection of analytes in exhaled breath |
US13/394,609 Expired - Fee Related US10520439B2 (en) | 2009-09-09 | 2010-09-09 | System and method for drug detection in exhaled breath |
US13/739,607 Active US8705029B2 (en) | 2009-09-09 | 2013-01-11 | System and method for detection of analytes in exhaled breath |
US14/222,696 Abandoned US20140204374A1 (en) | 2009-09-09 | 2014-03-24 | System and Method for Detection of Analytes in Exhaled Breath |
US16/678,761 Active 2031-10-03 US11567011B2 (en) | 2009-09-09 | 2019-11-08 | System and method for drug detection in exhaled breath |
Country Status (16)
Country | Link |
---|---|
US (6) | US8368883B2 (en) |
EP (6) | EP3336543A1 (en) |
JP (2) | JP5992328B2 (en) |
CN (1) | CN102498398B (en) |
AU (1) | AU2010294183B2 (en) |
BR (1) | BR112012005198A8 (en) |
CA (2) | CA2771830C (en) |
DK (1) | DK2765420T3 (en) |
EA (1) | EA023922B1 (en) |
ES (2) | ES2484515T3 (en) |
HU (1) | HUE038136T2 (en) |
MX (1) | MX2012002976A (en) |
NO (1) | NO2765420T3 (en) |
TR (1) | TR201802101T4 (en) |
WO (2) | WO2011029889A1 (en) |
ZA (1) | ZA201201304B (en) |
Families Citing this family (81)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20110178420A1 (en) * | 2010-01-18 | 2011-07-21 | Trent Ridder | Methods and apparatuses for improving breath alcohol testing |
TR201802101T4 (en) | 2009-09-09 | 2018-03-21 | Sensa Bues Ab | Drug detection in the given breath. |
US9417232B2 (en) * | 2009-10-02 | 2016-08-16 | Bi Mobile Breath, Inc. | Sobriety monitoring system |
US9228997B2 (en) | 2009-10-02 | 2016-01-05 | Soberlink, Inc. | Sobriety monitoring system |
US8707758B2 (en) | 2009-10-02 | 2014-04-29 | Soberlink, Inc. | Sobriety monitoring system |
EP2591331A4 (en) | 2010-07-06 | 2017-06-07 | Deton Corp. | System for airborne bacterial sample collection and analysis |
US8814804B2 (en) * | 2010-12-13 | 2014-08-26 | Iph, Llc | Interactive blood-alcohol content tester |
EP2518499B1 (en) | 2011-03-09 | 2015-06-10 | Sensa Bues AB | A portable sampling device and method for drug detection from exhaled breath |
EP2498091A1 (en) * | 2011-03-09 | 2012-09-12 | Sensa Bues AB | A vehicle interlocking system and method based on detection of analytes in exhaled breath |
US20120327407A1 (en) * | 2011-06-21 | 2012-12-27 | University Of Georgia Research Foundation, Inc. | Independent Component Analysis of Surface-Enhanced Raman Scattering (SERS) Signals |
WO2013006391A1 (en) * | 2011-07-01 | 2013-01-10 | 3M Innovative Properties Company | A method and apparatus for screening drug offenders |
US9255842B2 (en) | 2011-07-13 | 2016-02-09 | Thermo Scientific Portable Analytical Instruments Inc. | Heroin detection by raman spectroscopy from impure compositions comprising an interfering fluorescent contaminant |
US20140276100A1 (en) * | 2012-02-01 | 2014-09-18 | Invoy Technologies | System for measuring breath analytes |
US9636044B2 (en) | 2012-02-01 | 2017-05-02 | Invoy Technologies, Llc | Breath analyzer with expandable range of measurement |
US9689864B2 (en) | 2012-02-01 | 2017-06-27 | Invoy Technologies, Llc | Method and apparatus for rapid quantification of an analyte in breath |
EP3667317A1 (en) | 2012-03-08 | 2020-06-17 | Sensa Bues AB | A portable sampling device and method for detection of biomarkers in exhaled breath |
WO2013174387A1 (en) | 2012-05-23 | 2013-11-28 | Danmarks Tekniske Universitet | A system for obtaining an optical spectrum |
US9617582B2 (en) | 2012-09-04 | 2017-04-11 | University Of Maryland College Park | Human exhaled aerosol droplet biomarker system and method |
EP2706355A1 (en) * | 2012-09-11 | 2014-03-12 | Sensa Bues AB | System and method for eluting and testing substance from exhaled aerosol sample |
CN105339486B (en) * | 2013-03-12 | 2018-12-21 | 德汤公司 | The system collected and analyzed for breath sample |
CN103163268A (en) * | 2013-03-21 | 2013-06-19 | 北京华新安科科技有限公司 | Medical breath testing device and testing method thereof |
JP2016518612A (en) * | 2013-05-16 | 2016-06-23 | ロレアル | Apparatus and method for determining a diffusion profile of at least one molecule from the skin |
US9665689B2 (en) | 2013-05-17 | 2017-05-30 | Viavi Solutions Inc. | Medication assurance system and method |
CN103487481B (en) * | 2013-10-16 | 2016-01-13 | 无锡市尚沃医疗电子股份有限公司 | A kind of expiration ammonia analyser |
US9970950B1 (en) | 2014-03-09 | 2018-05-15 | Hound Labs, Inc. | Method and apparatus for detecting acute use of target substance(s) |
JP6311387B2 (en) * | 2014-03-26 | 2018-04-18 | 株式会社島津製作所 | Compound analysis method, compound analyzer, and compound analysis program |
CA2850998A1 (en) | 2014-04-18 | 2015-10-18 | Thc Breathalyzer, Inc. | Cannabis drug detection device |
EP3161121A4 (en) | 2014-06-27 | 2017-12-27 | Pulse Health LLC | Fluorescence detection assembly |
WO2016013003A1 (en) * | 2014-07-21 | 2016-01-28 | Technion Research & Development Foundation Limited | Compositions for direct breath sampling |
US20160061807A1 (en) * | 2014-08-27 | 2016-03-03 | Lifeloc Technologies, Inc. | Spectral signature drug detection |
KR101711425B1 (en) * | 2014-12-19 | 2017-03-02 | 대전대학교 산학협력단 | Fine particles sampling apparatus and analysis method of fine particles using the same |
US9726684B1 (en) | 2015-01-18 | 2017-08-08 | Hound Labs, Inc. | Compositions for target substance detection and measurement |
CN104655829A (en) * | 2015-03-06 | 2015-05-27 | 张波 | Indicating system for oral care |
US9733225B2 (en) * | 2015-03-07 | 2017-08-15 | Matthew David Armstrong | Spectroscopic breath detector |
WO2016166623A1 (en) * | 2015-04-17 | 2016-10-20 | Cannabix Technologies Inc. | Cannabis drug detection device |
CN104914089B (en) * | 2015-06-18 | 2017-10-27 | 清华大学 | The method for carrying out semi-quantitative analysis to trace mixture with SERS |
US11726102B2 (en) * | 2015-07-24 | 2023-08-15 | Washington State University | Particle-based drug detection method and device embodiments |
US9922508B2 (en) | 2015-10-09 | 2018-03-20 | Soberlink Healthcare, Llc | Bioresistive-fingerprint based sobriety monitoring system |
CN105510415B (en) * | 2016-01-04 | 2017-12-29 | 广西民族大学 | A kind of preparation method of the Meprobamate molecular imprinting electrochemical sensor of highly sensitive functionalization golden nanometer particle doping |
US10557844B2 (en) | 2016-04-08 | 2020-02-11 | Soberlink Healthcare, Llc | Bioresistive-fingerprint based sobriety monitoring system |
US10502665B2 (en) | 2016-04-18 | 2019-12-10 | University Of Maryland, College Park | Aerosol collection system and method |
JP6861270B2 (en) * | 2016-04-25 | 2021-04-21 | アウルストーン・メディカル・リミテッドOwlstone Medical Limited | Systems and devices for capturing exhaled breath samples |
CN109475325A (en) * | 2016-05-13 | 2019-03-15 | 艾克雷泽私人有限公司 | Change the test macro of the substance of spirit |
US9933445B1 (en) | 2016-05-16 | 2018-04-03 | Hound Labs, Inc. | System and method for target substance identification |
US9921234B1 (en) * | 2016-06-17 | 2018-03-20 | Hound Labs, Inc. | Compositions and methods for detection of target constituent in exhaled breath |
CN106770811A (en) * | 2016-11-10 | 2017-05-31 | 中国科学院声学研究所 | A kind of method and apparatus for detecting drugs content in expiration |
GB201704367D0 (en) * | 2017-03-20 | 2017-05-03 | Exhalation Tech Ltd | A breath condensate analyser |
WO2018200794A1 (en) * | 2017-04-28 | 2018-11-01 | University Of Pittsburgh-Of The Commonwealth System Of Higher Education | Tetrahydrocannabinol sensor |
US11026596B1 (en) | 2017-05-19 | 2021-06-08 | Hound Labs, Inc. | Detection and measurement of target substance in exhaled breath |
US11624703B2 (en) | 2017-08-02 | 2023-04-11 | Vox Biomedical Llc | Virus sensing in exhaled breath by infrared spectroscopy |
US10969333B2 (en) | 2017-08-02 | 2021-04-06 | Vox Biomedical Llc | Sensing cannabis and opioids in exhaled breath by infrared spectroscopy |
US11187711B1 (en) | 2017-09-11 | 2021-11-30 | Hound Labs, Inc. | Analyte detection from breath samples |
TWI663400B (en) | 2017-09-28 | 2019-06-21 | 國立臺灣大學 | Sensing paper and method of sensing abused drugs |
AU201815511S (en) | 2018-05-07 | 2018-12-17 | Sensa Bues Ab | Breath sampling device |
MX2021001203A (en) * | 2018-07-31 | 2021-06-15 | Univ North Texas | Techniques for rapid detection and quantitation of volatile organic compounds (vocs) using breath samples. |
US11721533B1 (en) | 2018-07-31 | 2023-08-08 | Inspectir Systems, Llc | Techniques for rapid detection and quantitation of volatile organic compounds (VOCS) using breath samples |
US11879890B1 (en) | 2018-07-31 | 2024-01-23 | Inspectir Systems, Llc | Techniques for rapid detection and quantitation of volatile organic compounds (VOCS) using breath samples |
US11874270B1 (en) | 2018-07-31 | 2024-01-16 | Inspectir Systems, Llc | Techniques for rapid detection and quantitation of volatile organic compounds (VOCs) using breath samples |
US11662340B1 (en) | 2018-07-31 | 2023-05-30 | InspectIR Systems, Inc. | Techniques for rapid detection and quantitation of volatile organic compounds (VOCS) using breath samples |
US11841359B1 (en) | 2018-07-31 | 2023-12-12 | Inspectir Systems, Llc | Techniques for portable rapid detection and quantitation of volatile organic compounds (VOCS) using breath samples |
US11841372B1 (en) | 2018-07-31 | 2023-12-12 | Inspectir Systems, Llc | Techniques for rapid detection and quantitation of volatile organic compounds (VOCs) using breath samples |
US11454628B2 (en) * | 2018-08-06 | 2022-09-27 | Northeastern University | On-surface mass tagging |
US11426097B1 (en) | 2018-10-17 | 2022-08-30 | Hound Labs, Inc. | Rotary valve assemblies and methods of use for breath sample cartridge systems |
DE202018106075U1 (en) * | 2018-10-24 | 2020-01-27 | Securetec Detektions-Systeme Ag | Sample analysis device and removal element for a sample analysis device |
US20200245898A1 (en) | 2019-01-31 | 2020-08-06 | Hound Labs, Inc. | Single-use Microfluidic Cartridge for Detection of Target Chemical Presence in Human Breath |
US11977086B2 (en) * | 2019-03-21 | 2024-05-07 | Hound Labs, Inc. | Biomarker detection from breath samples |
IT201900005362A1 (en) * | 2019-04-08 | 2020-10-08 | Centro Regionale Information Communication Tech Cerict Scarl | NEEDLE OR CATHETER PROVIDED WITH A PLURALITY OF OPTICAL FIBERS |
WO2021011470A1 (en) | 2019-07-12 | 2021-01-21 | Massachusetts Institute Of Technology | Systems and methods for stochastically modulated raman spectroscopy |
JP2023528725A (en) * | 2020-04-03 | 2023-07-06 | ゼテオ テック、 インク. | Diagnosis of respiratory diseases using breath and aerosol analysis |
WO2021219749A1 (en) | 2020-04-30 | 2021-11-04 | Vitalograph (Ireland) Ltd. | A sampling device |
US11933731B1 (en) | 2020-05-13 | 2024-03-19 | Hound Labs, Inc. | Systems and methods using Surface-Enhanced Raman Spectroscopy for detecting tetrahydrocannabinol |
EP4171694A4 (en) * | 2020-06-30 | 2024-05-01 | Air Clenz Systems Llc | Enhanced exhaled air collector and air purification unit and system |
US20220034761A1 (en) * | 2020-07-29 | 2022-02-03 | Shazi S. Iqbal | Microbial sample collection, transport and processing apparatus and method |
WO2022093876A1 (en) * | 2020-10-26 | 2022-05-05 | Innovaprep Llc | Multi-function face masks |
US11806711B1 (en) | 2021-01-12 | 2023-11-07 | Hound Labs, Inc. | Systems, devices, and methods for fluidic processing of biological or chemical samples using flexible fluidic circuits |
US20240148274A1 (en) * | 2021-03-31 | 2024-05-09 | Zeteo Tech, Inc. | Diagnosis of respiratory diseases by capturing aerosolized biomaterial particles using packed bed systems and methods |
WO2022221198A1 (en) * | 2021-04-12 | 2022-10-20 | Proveris Scientific Corporation | Aerosol sample collection device |
RU2768760C1 (en) * | 2021-07-02 | 2022-03-24 | Василий Алексеевич Елиферов | Method of making cartridges for direct mass spectrometric analysis |
KR102653164B1 (en) * | 2021-11-16 | 2024-04-01 | 경희대학교 산학협력단 | Composition for Selectively Detecting Amphetamine-Type Stimulants, Colorimetric Sensor Comprising the Same, and Uses Thereof |
SE2250675A1 (en) * | 2022-06-03 | 2023-12-04 | Munkplast Ab | Method and system for preparing a breath sample for analysis |
WO2024081931A1 (en) * | 2022-10-14 | 2024-04-18 | Oreagan Iii Francis J | Breathalyzer test container assembly for storing and releasing gases |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030028120A1 (en) * | 1999-08-02 | 2003-02-06 | Mault James R. | Metabolic calorimeter employing resperatory gas analysis |
US20050048660A1 (en) * | 2003-09-02 | 2005-03-03 | Case Western Reserve University | Biomarker of maternal alcohol use during pregnancy |
US20050051719A1 (en) * | 1999-07-21 | 2005-03-10 | Sionex Corporation | Systems for differential ion mobility analysis |
US20050065446A1 (en) * | 2002-01-29 | 2005-03-24 | Talton James D | Methods of collecting and analyzing human breath |
US20050137491A1 (en) * | 2002-12-20 | 2005-06-23 | Paz Frederick M. | Breath aerosol management and collection system |
US20070023627A1 (en) * | 2003-02-10 | 2007-02-01 | Waters Investments Limited | Adsorption, detection and identification of components of ambient air with desorption/ionization on silicon mass spectrometry (dios-ms) |
US20070156211A1 (en) * | 2004-04-19 | 2007-07-05 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Lumen-traveling device |
Family Cites Families (78)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2626642B1 (en) | 1976-06-14 | 1977-12-15 | Werner Prof Dr-Ing Adrian | DEVICE FOR MEASURING THE CONCENTRATION OF GASES |
US4156143A (en) | 1978-01-10 | 1979-05-22 | Werner Adrian | Device for measuring the concentration of a gas |
US4292978A (en) | 1979-12-26 | 1981-10-06 | Guth Richard U | Breath test mouthpiece |
US4809810A (en) * | 1986-05-01 | 1989-03-07 | Autosense Corporation | Breath alcohol analyzer |
GB8911627D0 (en) | 1989-05-19 | 1989-07-05 | Intersurgical Guernsey Ltd | Improvements in filters |
US5042501A (en) | 1990-05-01 | 1991-08-27 | Battelle Memorial Institute | Apparatus and method for analysis of expired breath |
US5467776A (en) | 1993-07-28 | 1995-11-21 | The Brewer Company | Air sampling device and method for sampling exhaled air |
US5518002A (en) * | 1993-10-22 | 1996-05-21 | Medtrac Technologies, Inc. | Portable electronic spirometric device |
US5465728A (en) * | 1994-01-11 | 1995-11-14 | Phillips; Michael | Breath collection |
US5478377A (en) * | 1994-07-22 | 1995-12-26 | The United States Of America As Represented By The Secretary Of The Army | Filter for a respiratory device |
WO1997000444A1 (en) | 1995-06-19 | 1997-01-03 | British Technology Group Limited | Animal exhalation monitoring |
US5814516A (en) * | 1995-10-13 | 1998-09-29 | Lockheed Martin Energy Systems, Inc. | Surface enhanced Raman gene probe and methods thereof |
JPH09243639A (en) * | 1996-03-06 | 1997-09-19 | Matsushita Electric Ind Co Ltd | Liquid intake-tape organic-substance detection apparatus |
US5787786A (en) | 1996-05-09 | 1998-08-04 | Sauer-Sundstrand - Control Concepts | Dual hydraulic oscillator for the reciprocating cutter of an agricultural machine |
US5859362A (en) | 1996-10-22 | 1999-01-12 | Revenue Canada | Trace vapor detection |
US5834626A (en) | 1996-11-29 | 1998-11-10 | De Castro; Emory S. | Colorimetric indicators for breath, air, gas and vapor analyses and method of manufacture |
DE19718924A1 (en) * | 1997-04-28 | 1998-10-29 | Medium Sensor Gmbh | Apparatus to recover component fractions from exhaled air |
US6097480A (en) | 1998-01-27 | 2000-08-01 | Kaplan; Milton | Vehicle interlock system |
US6209541B1 (en) * | 1998-02-25 | 2001-04-03 | Sims Portex Inc. | Hydrophobic electrostatic breathing filters, and methods of manufacturing the same |
US6432175B1 (en) * | 1998-07-02 | 2002-08-13 | 3M Innovative Properties Company | Fluorinated electret |
JP2002526769A (en) * | 1998-10-02 | 2002-08-20 | カリフォルニア インスティチュート オブ テクノロジー | Conductive organic sensors, arrays and methods of use |
US6623977B1 (en) | 1999-11-05 | 2003-09-23 | Real-Time Analyzers, Inc. | Material for surface-enhanced Raman spectroscopy, and SER sensors and method for preparing same |
US20050233459A1 (en) * | 2003-11-26 | 2005-10-20 | Melker Richard J | Marker detection method and apparatus to monitor drug compliance |
WO2001084112A1 (en) | 2000-05-01 | 2001-11-08 | Respiratory Research, Inc. | Method and device for collecting and analyzing exhaled breath |
US6390987B1 (en) * | 2000-08-03 | 2002-05-21 | Ge Marquette Medical Systems, Inc. | Method and apparatus for separating water and gas in a gas analyzer system |
US6553241B2 (en) | 2000-08-31 | 2003-04-22 | Mallinckrodt Inc. | Oximeter sensor with digital memory encoding sensor expiration data |
WO2005098429A2 (en) | 2000-11-08 | 2005-10-20 | University Of Florida Research Foundation, Inc. | System and method for real-time diagnosis, treatment, and therapeutic drug monitoring |
US20070258894A1 (en) | 2000-11-08 | 2007-11-08 | Melker Richard J | System and Method for Real-Time Diagnosis, Treatment, and Therapeutic Drug Monitoring |
US20050054942A1 (en) * | 2002-01-22 | 2005-03-10 | Melker Richard J. | System and method for therapeutic drug monitoring |
US6623997B2 (en) | 2000-12-15 | 2003-09-23 | Agilent Technologies, Inc. | Method for burn-in processing of optical transmitter arrays using a submount substrate |
EP1405067A2 (en) | 2001-05-23 | 2004-04-07 | University Of Florida | Method and apparatus for detecting illicit substances |
EP1393069A1 (en) * | 2001-05-24 | 2004-03-03 | The University Of Florida | Method and apparatus for detecting environmental smoke exposure |
EP1392262A1 (en) * | 2001-05-24 | 2004-03-03 | Alexza Molecular Delivery Corporation | Delivery of drug esters through an inhalation route |
US6547450B2 (en) * | 2001-06-27 | 2003-04-15 | Fitel Usa Corp. | Quick-release dust cap for an optical plug |
US20030023182A1 (en) | 2001-07-26 | 2003-01-30 | Mault James R. | Respiratory connector for respiratory gas analysis |
CN1620502A (en) * | 2001-11-09 | 2005-05-25 | 陶氏环球技术公司 | Enzyme-based system and sensor for measuring acetone |
AU2002231066A1 (en) | 2001-12-21 | 2003-07-24 | Pierre M. Crespo | Substance testing devices with photo identification |
US20060160134A1 (en) * | 2002-10-21 | 2006-07-20 | Melker Richard J | Novel application of biosensors for diagnosis and treatment of disease |
US20130190639A1 (en) * | 2002-12-20 | 2013-07-25 | The Charlotte-Mecklenburg Hospital Authority | Utilizing lipopolysaccharide in exhaled breath condensate to diagnose gram negative pneumonia |
US20050013749A1 (en) * | 2003-03-27 | 2005-01-20 | Mcallister Clinton J. | One piece catalytic converter housing with integral end cone |
JP3800422B2 (en) | 2003-03-31 | 2006-07-26 | 株式会社日立製作所 | Method and apparatus for detecting a specific drug |
JP2004361160A (en) | 2003-06-03 | 2004-12-24 | Terametsukusu Kk | Expiration condensate collection apparatus |
CA2433975C (en) * | 2003-06-27 | 2012-01-17 | Dana Canada Corporation | Ribbed mounting bracket for heat exchangers |
US9022027B2 (en) * | 2004-02-20 | 2015-05-05 | Pneumoflex Systems, Llc | Nebulizer with intra-oral vibrating mesh |
US7713849B2 (en) | 2004-08-20 | 2010-05-11 | Illuminex Corporation | Metallic nanowire arrays and methods for making and using same |
US7450227B2 (en) | 2004-09-22 | 2008-11-11 | The Penn State Research Foundation | Surface enhanced Raman spectroscopy (SERS) substrates exhibiting uniform high enhancement and stability |
DE102004049064B3 (en) * | 2004-10-08 | 2006-05-18 | Dräger Safety AG & Co. KGaA | Method for distinguishing wet and dry gas with a breath alcohol meter |
US7393692B2 (en) | 2004-10-18 | 2008-07-01 | Real-Time Analyzers, Inc. | SERS method for rapid pharmacokinetic analysis of drugs in saliva |
GB2419940B (en) | 2004-11-04 | 2007-03-07 | Mesophotonics Ltd | Metal nano-void photonic crystal for enhanced raman spectroscopy |
US8627821B2 (en) * | 2005-01-10 | 2014-01-14 | Pulmatrix, Inc. | Method and device for decreasing contamination |
US7279132B2 (en) | 2005-01-12 | 2007-10-09 | Delphi Technologies, Inc. | Chemical vapor sensor having an active and a passive measurement mode |
JP4564406B2 (en) | 2005-05-25 | 2010-10-20 | 株式会社日立製作所 | Exhalation collection filter, exhalation collection device, exhalation analysis system, and exhalation analysis method |
WO2007020640A2 (en) * | 2005-08-16 | 2007-02-22 | Oridion Medical 1987, Ltd. | Breath sampling device and method for using same |
UA82962C2 (en) * | 2005-12-02 | 2008-05-26 | Sms Demag Ag | Method and smelting unit for obtaining steel with high manganese and low carbon content |
WO2007087625A2 (en) * | 2006-01-26 | 2007-08-02 | Euliano Neil R | Breath and breath condensate analysis system and associated methods |
US8348853B2 (en) * | 2006-02-06 | 2013-01-08 | Deka Products Limited Partnership | System, method and device for aiding in the diagnosis of respiratory dysfunction |
JP2009529673A (en) * | 2006-03-07 | 2009-08-20 | ユニバーシティ オブ フロリダ リサーチ ファウンデーション,インク. | Medication compliance monitoring system |
US7414239B2 (en) * | 2006-04-27 | 2008-08-19 | Ricoh Company, Ltd. | Optical-scanning apparatus and image forming apparatus |
CN101490059A (en) * | 2006-05-15 | 2009-07-22 | 南丹麦大学 | Porphyrinogen derivatives useful as explosives detection markers |
JP4856514B2 (en) | 2006-10-20 | 2012-01-18 | 株式会社日立製作所 | Exhalation component collector, exhalation component collection device, exhalation component collector manufacturing method, exhalation component analysis device, and exhalation component analysis method |
WO2008088780A1 (en) * | 2007-01-12 | 2008-07-24 | University Of Pittsburgh-Of The Commonwealth System Of Higher Education | Detection of nitric oxide by nanostructured sensor |
US8078334B2 (en) | 2007-01-23 | 2011-12-13 | Alan Goodrich | Unobtrusive system and method for monitoring the physiological condition of a target user of a vehicle |
WO2008092198A1 (en) * | 2007-01-31 | 2008-08-07 | Euan Roger Tovey | A collection device for sampling exhaled airstreams |
JP5011026B2 (en) | 2007-08-21 | 2012-08-29 | シャープ株式会社 | SPECIFIC GAS COMPONENT CONCENTRATION DEVICE USING POROUS STRUCTURE AND SPECIFIC GAS COMPONENT DETECTION DEVICE |
GB0717433D0 (en) | 2007-09-07 | 2007-10-17 | Bedfont Scient Ltd | Apparatus and method |
EP2203563A4 (en) * | 2007-09-17 | 2013-07-24 | Univ New York State Res Found | Detection of h. pylori utilizing unlabeled urea |
AU2008307788A1 (en) * | 2007-10-02 | 2009-04-09 | Almstrand, Anne-Charlotte | Collection and measurement of exhaled particles |
CN101354394B (en) * | 2008-09-08 | 2012-10-10 | 尚沃医疗电子无锡有限公司 | Expiration nitric oxide detection device |
US20100121210A1 (en) * | 2008-10-15 | 2010-05-13 | University Of Memphis Research Foundation | Method and device for detection ofanalyte in vapor or gaseous sample |
WO2011008774A2 (en) * | 2009-07-13 | 2011-01-20 | Deka Products Limited Partnership | Devices, systems, and methods for aiding in the detection of a physiological abnormality |
US11534081B2 (en) * | 2009-08-06 | 2022-12-27 | Peter Theophilos Banos | Methods of and devices for monitoring the effects of cellular stress and damage resulting from radiation exposure |
US20110053173A1 (en) * | 2009-08-28 | 2011-03-03 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Game with detection capability |
TR201802101T4 (en) | 2009-09-09 | 2018-03-21 | Sensa Bues Ab | Drug detection in the given breath. |
EP2498091A1 (en) | 2011-03-09 | 2012-09-12 | Sensa Bues AB | A vehicle interlocking system and method based on detection of analytes in exhaled breath |
EP2518499B1 (en) | 2011-03-09 | 2015-06-10 | Sensa Bues AB | A portable sampling device and method for drug detection from exhaled breath |
EP3667317A1 (en) | 2012-03-08 | 2020-06-17 | Sensa Bues AB | A portable sampling device and method for detection of biomarkers in exhaled breath |
US9617582B2 (en) * | 2012-09-04 | 2017-04-11 | University Of Maryland College Park | Human exhaled aerosol droplet biomarker system and method |
EP3155758A4 (en) * | 2014-06-10 | 2018-04-11 | Sightline Innovation Inc. | System and method for network based application development and implementation |
-
2010
- 2010-09-09 TR TR2018/02101T patent/TR201802101T4/en unknown
- 2010-09-09 MX MX2012002976A patent/MX2012002976A/en active IP Right Grant
- 2010-09-09 US US13/394,979 patent/US8368883B2/en not_active Expired - Fee Related
- 2010-09-09 BR BR112012005198A patent/BR112012005198A8/en not_active Application Discontinuation
- 2010-09-09 CA CA2771830A patent/CA2771830C/en active Active
- 2010-09-09 NO NO14164314A patent/NO2765420T3/no unknown
- 2010-09-09 US US13/394,609 patent/US10520439B2/en not_active Expired - Fee Related
- 2010-09-09 EP EP17201359.1A patent/EP3336543A1/en not_active Withdrawn
- 2010-09-09 EP EP10751947.2A patent/EP2361387B1/en active Active
- 2010-09-09 DK DK14164314.8T patent/DK2765420T3/en active
- 2010-09-09 ES ES10751947.2T patent/ES2484515T3/en active Active
- 2010-09-09 EA EA201270386A patent/EA023922B1/en not_active IP Right Cessation
- 2010-09-09 EP EP14164315.5A patent/EP2765421A1/en not_active Withdrawn
- 2010-09-09 EP EP10754461.1A patent/EP2475977B1/en not_active Not-in-force
- 2010-09-09 JP JP2012528364A patent/JP5992328B2/en not_active Expired - Fee Related
- 2010-09-09 WO PCT/EP2010/063266 patent/WO2011029889A1/en active Application Filing
- 2010-09-09 CA CA3029712A patent/CA3029712A1/en active Pending
- 2010-09-09 ES ES14164314.8T patent/ES2659738T3/en active Active
- 2010-09-09 AU AU2010294183A patent/AU2010294183B2/en not_active Ceased
- 2010-09-09 CN CN201080040304.0A patent/CN102498398B/en active Active
- 2010-09-09 EP EP15170749.4A patent/EP2982980A1/en not_active Withdrawn
- 2010-09-09 WO PCT/EP2010/063265 patent/WO2011029888A1/en active Application Filing
- 2010-09-09 HU HUE14164314A patent/HUE038136T2/en unknown
- 2010-09-09 EP EP14164314.8A patent/EP2765420B1/en active Active
-
2012
- 2012-02-22 ZA ZA2012/01304A patent/ZA201201304B/en unknown
-
2013
- 2013-01-11 US US13/739,607 patent/US8705029B2/en active Active
-
2014
- 2014-03-24 US US14/222,696 patent/US20140204374A1/en not_active Abandoned
- 2014-11-06 JP JP2014226506A patent/JP2015057607A/en active Pending
-
2019
- 2019-11-08 US US16/678,761 patent/US11567011B2/en active Active
-
2022
- 2022-12-23 US US18/088,439 patent/US20230125894A1/en active Pending
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050051719A1 (en) * | 1999-07-21 | 2005-03-10 | Sionex Corporation | Systems for differential ion mobility analysis |
US20030028120A1 (en) * | 1999-08-02 | 2003-02-06 | Mault James R. | Metabolic calorimeter employing resperatory gas analysis |
US20050065446A1 (en) * | 2002-01-29 | 2005-03-24 | Talton James D | Methods of collecting and analyzing human breath |
US20050137491A1 (en) * | 2002-12-20 | 2005-06-23 | Paz Frederick M. | Breath aerosol management and collection system |
US20070023627A1 (en) * | 2003-02-10 | 2007-02-01 | Waters Investments Limited | Adsorption, detection and identification of components of ambient air with desorption/ionization on silicon mass spectrometry (dios-ms) |
US20050048660A1 (en) * | 2003-09-02 | 2005-03-03 | Case Western Reserve University | Biomarker of maternal alcohol use during pregnancy |
US20070156211A1 (en) * | 2004-04-19 | 2007-07-05 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Lumen-traveling device |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11567011B2 (en) | System and method for drug detection in exhaled breath | |
Yuan et al. | Solid-phase microextraction fiber in face mask for in vivo sampling and direct mass spectrometry analysis of exhaled breath aerosol | |
JP6332597B2 (en) | Portable sampling device and method for sampling drug substance from exhaled breath | |
US7153272B2 (en) | Methods of collecting and analyzing human breath | |
US10359417B2 (en) | Portable sampling device and method for detection of biomarkers in exhaled breath | |
JP2013504074A5 (en) | ||
US20150226726A1 (en) | System and Method for Eluting and Testing Substance From Exhaled Aerosol Sample | |
CN104939831B (en) | The system and method and application thereof of sample are collected from the expiratory air of subject | |
Huang et al. | Exhaled breath analysis of non-volatile drugs: Towards clinical applications |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: SENSA BUES AB, SWEDEN Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:PALMSKOG, GOERAN;BECK, OLOF;SIGNING DATES FROM 20120323 TO 20120527;REEL/FRAME:062198/0681 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |